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The most exciting phrase to hear in science, 
the one that heralds new discoveries, is not Eureka!  
but rather, "hmm.... that's funny...." 
 
(Isaac Asimov) 
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Summary 
 
CLEC-1 and CLEC-2 belong to a family of C-type lectin-like receptors with important 
functions in the immune system, e.g. as pattern recognition receptors on monocytic 
and dendritic cells. 
The first part of this work was devoted to evaluate the expression of CLEC-2 and 
CLEC-1 in subsets of peripheral blood cells. In monocytes and granulocytes low to 
moderate levels of mRNA for both receptors were detected, platelets contained mRNA 
for CLEC-2. T- and B-lymphocytes as well as NK cells did not display significant 
transcript levels for any of the two receptors. Using flow cytometry, CLEC-2 protein 
was detected on platelets and on CD14+ monocytic cells. CLEC-2 protein levels on 
monocytes showed a clear donor-dependent variation, which could potentially indicate 
different infection states. Whereas platelets readily adhered in adhesion assays to 
cells expressing the CLEC-2 ligand podoplanin, the level of CLEC-2 expression on 
monocytes apparently was not sufficient to reveal binding in this cellular assay.  
In contrast to CLEC-2 and despite it contains all characteristics of typical lectin-like 
receptors, CLEC-1 could never be detected on the cell surface although significant 
mRNA and intracellular protein levels were detected. Neither pro-inflammatory stimuli 
nor infection with different pathogens induced its transport to the cell surface. Since 
immunofluorescence staining and cell fractionation experiments revealed a membrane 
bound intracellular pattern resembling that of the endoplasmic reticulum resident 
protein Calnexin, it appears that CLEC-1 may have an intracellular localization and 
function comparable to some of the Toll-like receptors (TLR). Following treatment of 
dendritic cells with known ligands of intracellular TLR, a general pattern of 
downregulation of CLEC-1 mRNA could be detected. As these stimuli trigger 
maturation of dendritic cells, this might indicate a role for CLEC-1 in immature 
dendritic cells.  
In the fourth part of this work, we conducted an extensive comparison of the human 
and mouse genomic regions encoding the receptors of the myeloid subfamily of the 
NK receptor complexes. This revealed a large inversion of part of the region during 
the evolution of the primate lineage and identified two additional lectin-like genes, 
which we found to be also expressed in cells of the myeloid lineage.  
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Zusammenfassung 
 
CLEC-1 und CLEC-2 gehören zu einer Familie von C-Typ lektinähnlichen Rezeptoren 
mit wichtigen Funktionen im natürlichen Immunsystem wie etwa als Muster-
erkennungsrezeptoren auf monozytischen oder dendritischen Zellen.  
Der erste Teil dieser Arbeit bestand aus einer Analyse der Expression von CLEC-2 
und CLEC-1 in Blutzellfraktionen. In Monozyten und Granulozyten konnten für beide 
Rezeptoren niedrige bis moderate mRNA Mengen nachgewiesen werden, in 
Blutplättchen wurde CLEC-2 mRNA detektiert. T- und B-Lymphozyten sowie NK 
Zellen zeigten für beide Rezeptoren keine signifikanten Transkriptmengen. Durch 
Durchflusszytometrie konnte CLEC-2 Proteinexpression auf Blutplättchen und auf 
CD14+ monozytischen Zellen nachgewiesen werden. CLEC-2 Proteinmengen auf 
Monozyten zeigten klare Donorvarianz, was auf verschiedene Infektionszustände 
hindeuten könnte. Während Blutplättchen in Adhäsions-Assays klar an Zellen 
adherierten, die den CLEC-2 Liganden Podoplanin exprimierten, war die Höhe der 
CLEC-2 Expression auf Monozyten nicht ausreichend, um in diesem Versuch Bindung 
nachweisen zu können. 
Im Gegensatz zu CLEC-2 konnte CLEC-1 trotz nachweisbarer mRNA- und Protein- 
expression nie an der Zelloberfläche detektiert werden, obwohl CLEC-1 alle Merkmale 
von typischen lektinähnlichen Rezeptoren aufweist. Weder proinflammatorische 
Stimulation noch Infektion mit Pathogenen induzierten CLEC-1 Transport an die 
Zelloberfläche. Da Immunofluoreszenzfärbungen und Zellfraktionierungsexperimente 
ein membrangebundenes, intrazelluläres Expressionsmuster ähnlich Calnexin, einem 
Protein aus dem Endoplasmatischen Reticulum, zeigten, könnte CLEC-1 intrazellulär 
lokalisiert sein und eine Funktion ähnlich den Toll-like Rezeptoren (TLR) aufweisen. 
Stimualtion von dendritischen Zellen mit bekannten Liganden von intrazellulären TLR 
führte zu einer generellen Herunterregulierung von CLEC-1 mRNA Mengen. Da diese 
Stimuli die Reifung von dendritischen Zellen induzieren, könnte das auf eine Rolle von 
CLEC-1 in unreifen dendritischen Zellen hindeuten. 
Im vierten Teil dieser Arbeit, führten wir einen eingehenden Vergleich der humanen 
und murinen genomischen Regionen der myeloiden Familie des NK Rezeptor 
Komplexes durch. Dieser Vergleich zeigte eine Inversion eines Teiles der Region im 
Laufe der Evolution der Primatenlinie und identifizierte zwei zusätzliche in myeloiden 
Zellen exprimierte lektinähnliche Gene.  
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1) Introduction 
 
1.1) The innate immune system 
 
The immune system has been divided traditionally into innate and adaptive 
immunity. Compared to the complexity of the adaptive system, innate immunity 
seemed to be primitive and unsophisticated and therefore received little 
attention for a very long time. Although it had been discovered already in 1883 
by the Russian immunologist Ilya Mechnikov, who detected mobile cells 
surrounding, engulfing and destroying newly introduced bacteria in starfish, until 
about 10 years ago scientists concentrated to a large extent on the adaptive or 
acquired part of the immunity.  
However since the discovery of the Toll like receptors (TLR) in the mid 1990s 
(Nomura, Miyajima et al. 1994; Poltorak, He et al. 1998) it became evident that 
the innate immune system is of utmost importance providing not only the very 
first line of defence against a wide variety of challenges but also activating and 
especially channelling the adaptive immune system towards the appropriate 
way of defence against the detected pathogen (Medzhitov and Janeway 2000).  
As diverse as its functions are the different players of the innate immune 
system. The very first line of defense is formed by mechanical barriers like the 
skin or mucus secreted by the respiratory and gastrointestinal tract, second 
there are chemical compounds and proteins such as β-defensins, lysozyme and 
the complement system and at last there exist several different types of innate 
immune cells.  
The most important cell types responsible for implementing the functions of the 
innate immune system are natural killer (NK) cells, mast cells, eosinophils, 
basophils and the phagocytic cells including monocytes, macrophages, 
dendritic cells (DC) and neutrophils. These cell types are capable of identifying 
and eliminating pathogens due to the expression of various pattern recognition 
receptors, such as the Toll like family, which recognize a wide range of 
pathogen-associated molecular patterns (PAMP).  
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1.2) Monocytic and dendritic cells 
 
Both monocytes and dendritic cells belong to the myeloid lineage of blood cells 
and play crucial roles in the innate immune system as well as in the activation 
of appropriate adaptive immune functions. 
 
1.2.1) Monoytes 
 
Monocytes have been known for some time to be able to ingest material aiming 
on the one hand to simply eliminate waste and debris and on the other hand to 
destroy invading pathogens. Killing of pathogens is triggered by their binding to 
pattern recognition receptors expressed by the monocyte, causing the 
engulfment of the pathogen and the generation of the so called respiratory 
burst, resulting in release of reactive oxygen species (ROS) which destroy the 
engulfed pathogenic cell (El-Benna, Dang et al. 2005). 
However, in recent years it became obvious that the role of monocytes goes far 
beyond being a simple degradation machinery and that they also play important 
regulatory and effector roles in both the innate and the adaptive arm of the 
immune system (Dale, Boxer et al. 2008). Blood monocytes represent the 
significant amount of approximately 10% of circulating blood leukocytes in 
humans, they can be recruited to sites of injury or infection within minutes 
(Auffray, Fogg et al. 2007; Geissmann, Jung et al. 2003), they can take up 
antigen in peripheral tissues and transport it to the draining lymph nodes, 
produce cytokines and inflammatory or anti-inflammatory mediators 
(Sunderkotter, Nikolic et al. 2004) and they can give rise to macrophages and 
dendritic cells. Circulating monocytes also have been shown to be recruited 
directly from the blood to the T-cell areas of the lymph nodes during 
inflammation in the skin. To reach the peripheral lymph nodes (PLN), 
monocytes cross the membranes of high endothelial venules (HEV), which is 
the same route as taken by naive lymphocytes and subsets of memory cells. 
(Palframan, Jung et al. 2001; Geissmann, Auffray et al. 2008).  
Functions of monocytes in PLN have been shown to be neutralization of 
microorganisms (Delemarre, Kors et al. 1990), maintenance of the phenotype of 
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HEV (Hendriks, Eestermans et al. 1980), production of angiogenic factors 
(Sunderkotter, Steinbrink et al. 1994) and generation of lymphotropic cytokines 
and chemokines (Peters, Dupuis et al. 2000). Depending on the cytokine milieu 
monocytes may also differentiate into macrophages or DC. Exposure to IL-4 
and GM-CSF leads to DC differentiation (Sallusto and Lanzavecchia 1994), 
whereas stimulation with IL-6 and M-CSF causes generation of macrophages 
(Mitani, Katayama et al. 2000; Geissmann, Auffray et al. 2008). 
Considering these various functions it seems to be obvious, that there have to 
be distinct subsets of mononuclear phagocytes rather than one homogeneous 
population. In fact there are two main monocytic subtypes in humans, defined 
by the expression of CD14 and CD16, being the ‘classical’ CD14+CD16- and the 
‘pro-inflammatory' CD14+/-CD16+ cells (Passlick, Flieger et al. 1989) (CD 
nomenclature see Appendix C). 
CD16+ monocytes are found in larger numbers in the blood of patients with 
acute inflammation and infectious diseases (Mizuno, Toma et al. 2005; 
Fingerle, Pforte et al. 1993; Skrzeczynska, Kobylarz et al. 2002). They were 
reported to produce pro-inflammatory TNF-α in response to LPS stimulation, 
whereas CD14+CD16- monocytes produce anti-inflammatory IL10 
(Frankenberger, Sternsdorf et al. 1996; Belge, Dayyani et al. 2002).  
Thus instead of being mere precursors for dendritic cells or macrophages, 
recent data suggest that monocytes themselves are novel candidates even for 
shaping T-cell responses. LPS-activated monocytes have been shown to lead 
to differentiation of naive CD4+ T cells into Th17 helper cells, which have been 
characterized recently as a distinct lineage of pro-inflammatory T helper cells 
(Evans, Suddason et al. 2007; Wilson, Boniface et al. 2007). Th17 lymphocytes 
release the potent inflammatory cytokine IL-17 and are therefore involved in 
various autoimmune diseases including multiple sclerosis and asthma 
(Matusevicius, Kivisakk et al. 1999; Linden, Hoshino et al. 2000).  
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1.2.1) Dendritic cells 
 
Dendritic cells (DC) have been first described in 1972 (Steinman and Cohn 
1973) and are by now recognized to be the most important antigen presenting 
cells (APC), which are in their mature form capable of presenting processed 
antigenic peptides to T- and B-lymphocytes and thereby initiate potent immune 
responses to clear invading pathogens. Immature dendritic cells on the other 
hand, induce tolerance when they take up antigens from their environment in 
the absence of additional inflammatory stimulation (figure 1). 
 
A B 
 
 
 
Figure 1: Functions of immature and mature dendritic cells. A. Mature DC induce immunity. 
Inflammation induces maturation of DC and migration of large numbers of mature DC to 
draining lymph nodes. Mature DC express co-stimulatory molecules for the appropriate 
activation of CD4+ T-helper cells and CD8+ cytotoxic T-lymphocytes (CTL), B-lymphocytes and 
thereby initiate an adaptive immune response. CD4+CD25+ regulatory T-lymphocytes (TReg) are 
also expanded. B. Immature tissue DC induce tolerance. In the absence of inflammatory stimuli 
DC remain immature and antigens are presented to T- lymphocytes in the lymph node without 
co-stimulation, leading to the deletion of T cells or the generation of regulatory T cells.  ADCC, 
antibody-dependent cell-mediated cytotoxicity; NK, natural killer; TCR, T-cell receptor. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 
(Banchereau and Palucka 2005), copyright (2005) 
 
Dendritic cells can arise from both common myeloid and lymphocyte 
progenitors derived from CD34+ hematopoietic stem cells (Manz, Traver et al. 
2001) and there exist several subsets of dendritic cells defined by marker 
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expression and function. To date dendritic cells are devided into 
myeloid/conventional DC, plasmacytoid DC and epidermal Langerhans cells.  
In mice myeloid or conventional DC are further divided into two subsets, CD8+- 
and CD8--DC, which activate T cells toward Th1 and Th2 differentiation, 
respectively (Maldonado-Lopez, De Smedt et al. 1999; Vremec, Pooley et al. 
2000). They can be found only within lymph nodes, spleen and thymus 
(Steinman and Cohn 1973). In contrast, human myeloid DC seem to be less 
heterogeneous and are defined to be CD11c+CD14-CD1a+ (Ito, Liu et al. 2005). 
Plasmacytoid DC (pDC), which express CD123 as surface marker but are 
CD11c negative (Ito, Liu et al. 2005), are smaller and have shorter dendrites 
than conventional DC and resemble lymphocytes when immature. Whereas 
myeloid DC are very potent in macropinocytosis of antigens from their 
environment, immature pDC rather produce type 1 interferon (IFN) in response 
to viral infection (Panoskaltsis, Reid et al. 2004). They reside within lymph 
nodes, spleen, thymus, and bone marrow (Takeuchi and Furue 2007).  
Epidermal resident Langerhans cells (LC) are grouped together with dermal and 
intestinal dendritic cells. Upon encountering and uptake of invading pathogens, 
LC migrate into regional lymph nodes to present processed antigens to T 
lymphocytes (Romani, Holzmann et al. 2003). LC appear to be self-renewing 
and hardly need to be repopulated by circulating precursors unless their 
environment is disturbed like in skin damage or inflammation (Merad, Manz et 
al. 2002). If necessary repopulation is achieved by a subset of blood monocytes 
(Gr-1hi) which have been identified to be the circulating precursors of LC in vivo. 
Gr-1hi monocytes have been shown to migrate to inflamed areas of the 
epidermis and dermis, where they actively proliferate and subsequently 
differentiate into either dermal macrophages or epidermal LC (Ginhoux, Tacke 
et al. 2006). Therefore, apart CD34+ hematopoietic stem cells, monocytes 
circulating in the peripheral blood provide a further source of DC (Palucka, 
Taquet et al. 1998; Randolph, Beaulieu et al. 1998) especially the subset of 
CD16+ monocytes, which seems to be precommitted to differentiate into DC 
(Randolph, Sanchez-Schmitz et al. 2002). Despite of precommittment, different 
inflammatory and infectious stimuli such as ex vivo applied GM-CSF and IL-4 
also drive monocytes to develop into DC (Sallusto and Lanzavecchia 1994). 
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Considering their function, human mDC and pDC used to be termed DC1 and 
DC2, because they could be shown to preferentially induce Th1 and Th2 
lymphocytes, respectively (Rissoan, Soumelis et al. 1999). However, this view 
turned out to be too simplified when several studies showed that although there 
seems to be a tendency of DC subset-specific T-lymphocyte lineage induction, 
this process is in general highly dependent on the development, maturation or 
activation conditions applied (Takeuchi and Furue 2007).  
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1.3) Pattern recognition receptors of the innate immune system 
 
Pattern recognition receptors (PRR) are expressed on innate immune cells, 
which they render capable to detect and to react to pathogen-associated and 
danger-associated molecular patterns (PAMP and DAMP). PAMP are invariant 
pathogen specific structures shared by a class of pathogens and include 
bacterial carbohydrates such as lipopolysaccharide (LPS) of gram negative 
bacteria, peptidoglycans and lipotechoic acids from the cell wall of gram 
positive bacteria, bacterial carbohydrates containing mannose residues, the 
bacterial amino acid N-formylmethionine, fungal glucans, bacterial flagellin and 
bacterial and viral nucleic acids. DAMP on the other hand are endogenous 
molecules named endokines or alarmins which are either secreted actively by 
immune cells or released passively by dying cells and have activating effects on 
cells engaged in host defense and tissue repair expressing the corresponding 
pattern recognition receptor. Innate immune mediators with alarmin function 
include defensins, eosinophil-derived neurotoxin, cathelicidins and HMGB1 
(Oppenheim and Yang 2005). 
Pattern recognition receptors can be secreted like the complement activating 
mannose-binding protein (MBP) (Fraser, Koziel et al. 1998), localized to the 
cellular cytoplasm like retinoic acid-inducible gene-1 (RIG-1) (Kato, Sato et al. 
2005) or membrane associated like the families of Toll like receptors and C-type 
lectin-like receptors. 
 
1.3.1) C-type lectin-like receptors 
 
C-type lectin-like receptors are a family of type II transmembrane pattern 
recognition receptors characterized by their extracellular C-type lectin-like 
domains (CTLD). C-type lectins had been identified as proteins containing Ca2+-
dependent carbohydrate-recognition domains (CRD) (Zelensky and Gready 
2005; Weis, Taylor et al. 1998). C-type lectin-like receptors on the other hand 
are not only capable of recognizing carbohydrates but can in fact bind to a wide 
variety of different ligands and are also involved in other processes like cell-cell 
contact often even in a Ca2+-independent manner (Weis, Taylor et al. 1998). As 
shown in figure 2, C-type lectins expressed on dendritic cells contribute to 
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processes like adhesion to and migration through the endothelial cell layer and 
T-Lymphocyte activation, and they can function as both soluble and cell 
surface-bound antigen receptors (Figdor, van Kooyk et al. 2002).  
 
 
The common structure shared by all C-type lectins comprises a short 
cytoplasmic domain involved in downstream signaling, a transmembrane 
region, a flexible neck domain and the C-type lectin-like domains which contain 
6 highly conserved cystein residues and are involved in ligand binding 
(Zelensky and Gready 2005). 
 
1.3.2) Toll-like receptors 
 
Toll-like receptors (TLR) are a family of type I transmembrane glycoproteins 
characterized by the extracellular leucine-rich-repeat domain and the 
cytoplasmatic Toll/interleukin-1 receptor-like (TIR) domain involved in 
downstream signaling. They are expressed on various immune cells like 
 
Figure 2: Functions of C-
type lectin and C-type 
lectin-like receptors in 
dendritic cells. 
a. DC-SIGN and potentially 
DECTIN-1 might mediate 
DC-T-cell interactions. b. 
Membrane-bound lectins act 
as endocytic receptors for 
antigen capture. c. MMR and 
DC-SIGN may also be 
secreted as soluble antigen 
receptors and function as 
agglutinins and opsonins. d. 
MMR and DC-SIGN function 
in DC cell trafficking. BDCA-2 
(blood DC antigen 2); DC-
SIGN, (dendritic-cell specific 
ICAM-3 grabbing non-
integrin); ICAM, (intercellular 
adhesion molecule); MHC 
(major histocompatibility 
complex); MMR, 
(macrophage mannose 
receptor). Reprinted by 
permission from Macmillan 
Publishers Ltd: Nature 
Reviews Immunology 
(Figdor, van Kooyk et al. 
2002), copyright (2002)  
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dendritic cells, macrophages, B- and some types of T-lymphocytes and 
comprise one of the most important pattern recognition receptors family of the 
innate immune system (Miyake 2007). They rapidly sense pathogen invasion 
and thereby play a major role as the initiator of the innate as well as adaptive 
immune responses. 
 
 
Figure 3: The Toll like receptor signaling pathways and cooperations with other PRR. 
Overview showing known Toll like receptors as well as other important pattern recognition receptors 
with their corresponding ligands as well as utilized downstream signaling pathways and outcome of 
signaling. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology, 
(Trinchieri and Sher 2007; Boothroyd and Dubremetz 2008), copyright (2007) 
 
As shown in figure 3, each TLR specifically binds pathogen associated 
molecular patterns and thereby activates one of several possible TLR signaling 
pathways. TLR1, 2, 4, 5 and 6 are expressed on the cell surface and recognize 
bacterial and fungal cell wall components such as lipoproteins (TLR1, 2 and 6), 
lipopolysaccharides (TLR4) and flagellin (TLR5). TLR3, 7, 8 and 9 are found 
mostly within endosomes and recognize microbial nucleic acids such as double-
stranded RNA (TLR3), single-stranded RNA (TLR7 and 8) and non-methylated 
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CpG-motif containing DNA (TLR8). The ligands for TLR10, 12 and 13 still 
remain unidentified. TLR10 can be found in humans but not in mice, TLR8 is 
not functional in mice and TLR11, 12 and 13 are expressed in mice but not in 
humans (Poltorak, He et al. 1998; Aliprantis, Yang et al. 1999; Hemmi, 
Takeuchi et al. 2000; Alexopoulou, Holt et al. 2001; Hayashi, Smith et al. 2001; 
Heil, Hemmi et al. 2004).  
TLR utilize NFκB-, MAPK-, Myeloid differentiation primary response gene 88 
(MyD88)- and TIR-domain-containing adapter-inducing interferon-β (TRIF)-
dependent signaling pathways, resulting in different cellular responses. For 
example the intracellular TLR3 couples to the adaptor protein TRIF leading to 
the activation of TNF Receptor Associated Factor family of proteins-3 (TRAF-3) 
and Interferon response factor-3 (IRF3) and the secretion of IFN-β, which is 
required for an effective antiviral response. Other TLR couple to the adapter 
protein MyD88 (Takeda and Akira 2004; O'Neill 2006) which recruits interleukin-
1 receptor associated kinases (IRAK) and TRAF6 causing activation of NF-kB, 
c-Jun-NH2-kinases (JNK) and p38. The MyD88-coupled TLR signaling results 
in the synthesis of cytokines such as TNF-α, IL-6 and IL-1 (Kawai and Akira 
2005; Akira, Uematsu et al. 2006). 
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1.4) The human NK receptor complex 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
Figure 4: Organization of the human NK receptor complex on chromosome 12. A. Physical map 
of the 2.5 Mb region extending from the DCIR gene on the telomeric side to the PRB gene cluster on 
the centromeric side. B. Linkage and orientation of the C-type lectin-like genes in the centromeric 
part of the NK receptor gene complex (Hofer, Sobanov et al. 2001). 
 
The NK receptor family encoded within the NK gene complex located on the 
short arm of human chromosome 12 is one highly important family of C-type 
lectin-like receptors (figure 4). This genomic region has become the focus of 
intense investigations in recent years because of accumulating evidence 
supporting an important role of many of the encoded receptors in the immune 
system (Hofer, Sobanov et al. 2001; Ryan, Naper et al. 2001). Almost all of the 
proteins encoded in the NK receptor complex belong to the C-type lectin-like 
receptor family (Schnittger, Hamann et al. 1993; Yabe, McSherry et al. 1993; 
Lanier, Chang et al. 1994; Chang, Rodriguez et al. 1995), and have been 
reported to bind to carbohydrates such as β-glucans (Brown and Gordon 2001; 
Grunebach, Weck et al. 2002) and to various other ligands e.g. oxidised low 
density lipoprotein (Sawamura, Kume et al. 1997; Sakurai and Sawamura 
2003). Although the CTLD of most NK cell receptor proteins do not contain the 
sequence motifs associated with calcium and sugar binding, carbohydrate 
binding has been reported for some members of the group. For example, 
Osteoclast Inhibitory Lectin (OCIL) binds high molecular weight sulphated 
glycosaminoglycans (Gange, Quinn et al. 2004) and Mast cell Function-
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associated Antigen (MAFA) exhibits calcium-dependent binding to terminal 
mannose (Binsack and Pecht 1997).  
According to the expression patterns of the encoded proteins, the centromeric 
part of the NK receptor complex can be subdivided roughly into two regions. 
The genes at the centromeric side contain CD94 and the natural killer group 2 
(NKG2) gene family expressed mainly on NK and NKT cells (Hofer, Sobanov et 
al. 2001). Members of this part of the NK cell receptor family have undergone 
differential expansion in human and mouse. The Ly49 group is present only in 
mice, whereas the NK receptor protein (NKRP) 1 group, NKG2 proteins and 
CD94 are present in both species. Inhibitory NK receptors, for instance the 
NKG2A/CD94 heterodimer inhibit cytolytic activity of NK cell upon recognition of 
markers of healthy self cells, predominantly major histocompatibility (MHC)-
related molecules. Activating receptors like the NKG2C/CD94 heterodimer on 
the other hand stimulate cytolytic activity upon recognition of infected or 
transformed cells (Johansson and Hoglund 2006). 
A second part of the centromeric region of the NK complex directly telomeric of 
the CD94 gene codes for proteins predominantly expressed by cells of the 
myeloid lineage implying common regulatory mechanisms for each cluster. 
Therefore these clusters will subsequently be referred to as the NK and the 
myeloid cluster, respectively.  
The myeloid cluster spanning from the myeloid inhibitory C-type lectin-like 
receptor (MICL) to the CD94 gene, has been shown in recent years to code for 
several lectin-like receptors, namely C-type lectin-like receptor (CLEC)-1, 
CLEC-2, DECTIN-1 and oxidized low-density lipoprotein receptor-1 (LOX-1) 
(Sobanov, Bernreiter et al. 2001).  
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1.4) The myeloid subfamily of the NK receptor complex 
 
LOX-1, DECTIN-1, CLEC-1 and CLEC-2 encoded in the telomeric part of the 
human NK gene complex form the myeloid subfamily among the NK gene 
receptors. In contrast to the members of the NK subfamily they are not 
expressed on NK or NKT cells but show a more diverse expression pattern 
having been found among others in monocytic, dendritic and endothelial cells 
(Hofer, Sobanov et al. 2001; Sobanov, Bernreiter et al. 2001). All four receptors 
are type II transmembrane glycoproteins with a short N-terminal cytoplasmic 
region, a single transmembrane domain, a stalk and extracellular C-type 
lectin-like domains. These C-type lectin-like domains are highly conserved at 
six cysteine residues, which are necessary for forming the lectin-like fold (Shi, 
Niimi et al. 2001). Furthermore, all four receptors are likely to form 
homodimers via disulfide bonds within the stalk region (Xie, Matsunaga et al. 
2004; Ishigaki, Ohki et al. 2007). Concerning ligands and functions little is 
known about CLEC-1 whereas in part CLEC-2, but especially LOX-1 and 
DECTIN-1 have already been studied intensively (Kanazawa 2007). 
 
1.4.1) Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) 
 
LOX-1 was first identified in endothelial cells (Sawamura, Kume et al. 1997) but 
subsequently it could be shown to be also expressed on macrophages 
(Yoshida, Kondratenko et al. 1998), smooth muscle cells, monocytes (Draude, 
Hrboticky et al. 1999) and platelets (Chen, Kakutani et al. 2001). Its structure 
shows the common C-type lectin-like features and was revealed by 
crystallization of the CTLD and modeling of the neck domain based on the 
homology to the myosin heavy chain coiled-coil structure (figure 5A, 5B) (Ohki, 
Ishigaki et al. 2005). Its expression is regulated by pro-inflammatory stimuli 
such as tumour necrosis factor-α (TNF-α), phorbol ester (Kume, Murase et al. 
1998), transforming growth factor-β (TGF-β) (Minami, Kume et al. 2000), 
angiotensin II (Li, Zhang et al. 1999) and fluid shear stress (Murase, Kume et 
al. 1998). 
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A 
 
Figure 5: Crystal structure 
of LOX-1.  
A: Ribbon representation of 
the CTLD dimer structures of 
LOX-1 
B: Whole structure of LOX-1, 
modeled based on the crystal 
structure for the CTLD and the 
predicted model structure for 
the NECK domain.  
C: Comparison between the 
size of the bound OxLDL 
particle and three LOX-1 
dimers. Reprinted from 
Structure 13, Ohki, I., T. 
Ishigaki, et al., "Crystal 
structure of human lectin-like, 
oxidized low-density 
lipoprotein receptor 1 ligand 
binding domain and its ligand 
recognition mode to OxLDL.", 
(6): 905-17, Copyright (2005), 
with permission from Elsevier. 
 
LOX-1 levels are elevated in early atherosclerotic lesions, suggesting that LOX-
1 binding its ligand oxidized low density lipoprotein (oxLDL) is involved in the 
formation of atherosclerotic plaques (Chen, Kakutani et al. 2000; Mehta, 
Sanada et al. 2007). Taking into account the diameter of oxLDL (Segrest, 
Jones et al. 2001) and the fact that LOX-1 had previously been reported to 
exist as a hexamer on the cell surface (Xie, Matsunaga et al. 2004) the 
assembled structure of LOX-1 binding to oxLDL might look as depicted in 
figure 5C. Because of binding to oxLDL, LOX-1 has been postulated to act as 
scavenger receptor, which are defined by their ability to bind negatively charged 
molecules (Vohra, Murphy et al. 2006). 
The precise epitope on oxLDL recognized by LOX-1 is not known but it is 
thought to be peptide-based (Moriwaki, Kume et al. 1998). LOX-1 also 
recognizes other modified lipoprotein particles including hypochlorite-
modified high-density lipoprotein (Marsche, Levak-Frank et al. 2001) but not 
native LDL (Moriwaki, Kume et al. 1998). Furthermore, LOX-1 binds a high 
diversity of different ligands, being anionic polymers such as polyinosinic acid 
and carrageenan (Moriwaki, Kume et al. 1998), anionic phospholipids 
including phosphatidylserine (Murphy, Tacon et al. 2006), apoptotic bodies, 
A 
B C 
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aged cells (Oka, Sawamura et al. 1998), activated platelets (Kakutani, Masaki 
et al. 2000), AGE (advanced glycation end-products) (Jono, Miyazaki et al. 
2002) and both gram-positive and gram-negative bacteria (Shimaoka, Kume 
et al. 2001). 
Ligand binding to LOX-1 elevates reactive oxygen species (ROS) levels rapidly 
via activation of a membrane-bound nicotinamide adenine dinucleotide 
phosphate- (NADPH) oxidase (Chen, Xun et al. 2007). ROS then can activate 
two signal transduction pathways involving either p38 mitogen-activated protein 
kinase (MAPK) or phosphoinositide 3-kinase (PI3K), both causing activation of 
nuclear factor κB (NF-κB) and subsequent regulation of pro-inflammatory gene 
expression (Li, Saldeen et al. 2000; Nishimura, Akagi et al. 2004; Chen, Xun et 
al. 2007; Cominacini, Pasini et al. 2000). LOX-1 activation can also elevate 
CD40 and CD40L (CD40 ligand) levels. CD40-regulated intracellular signaling 
is an early immune response event and stimulates cytokine and chemokine 
secretion (Li, Liu et al. 2003; Dunn, Vohra et al. 2008).  
 
1.4.2) Dendritic cell associated C-type lectin-1 (DECTIN-1) 
 
DECTIN-1 also shares the common C-type lectin-like tertiary structure in its 
extracellular CTLD (figure 6A) and has been found to be expressed on different 
myeloid cells such as macrophages and dendritic cells (figure 6B). DECTIN-1 
mRNA can be alternatively spliced generating two predominant functional 
isoforms, one of which lacks the stalk region. Whereas the absence of the stalk 
does not seem to have significant effects on the ability of DECTIN-1 to 
recognize its ligand, the two isoforms show slightly different expression patterns 
(Willment, Gordon et al. 2001; Brown 2006; Heinsbroek, Taylor et al. 2006). 
Both isoforms, like most other C-type lectins, possess an extracellular 
carbohydrate-recognition domain (CRD) consisting of three CTLD and a 
cytoplasmic tail containing an immunoreceptor tyrosine-based activation 
(ITAM)-like motif (Brown 2006). 
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Figure 6: DECTIN-1 structure and function. A: Cartoon diagram of a DECTIN-1 homodimer 
binding a β-glucan molecule. Monomers are colored from blue at the N-terminus to red at the C-
terminus. The β-glucan is shown as green and red balls-and-sticks. Obtained from RCSB Protein 
Data Bank using entry ID: 2cl8, (Berman, Westbrook et al. 2000), (Brown, O'Callaghan et al. 2007). 
B: DECTIN-1-mediated signal transduction. On ligand binding, DECTIN-1 becomes tyrosine 
phosphorylated and induces an intracellular signaling cascade that results in various cell-specific 
responses. Due to the bridging of two DECTIN-1 molecules, their cytoplasmic tails can interact with 
spleen tyrosine kinase (SYK). Interactions with SYK can directly induce cellular responses, such as 
respiratory burst and interleukin-10 (IL-10) production. For the production of IL-2 additional signals 
from the TLR pathway are required. SYK contributes to phagocytosis in dendritic cells, but it is not 
required for this process in macrophages. Reprinted by permission from Macmillan Publishers Ltd: 
Nat Rev Immunol 6(1): 33-43 (Brown 2006), copyright (2006)  
 
DECTIN-1 recognizes β-1,3-glucans on a wide variety of fungal species, 
including Saccharomyces, Candida, Coccidoides, Pneumocystis and 
Aspergillus in a calcium-independent fashion (Brown 2006; Palma, Feizi et al. 
2006)  inducing a variety of cellular responses. These responses include 
respiratory burst, activation and regulation of phospholipase A2 (PLA2) and 
cyclooxygenase 2 (COX2), endocytosis and phagocytosis of ligands and the 
production of cytokines and chemokines, such as TNF-α, macrophage 
inflammatory protein 2 (MIP-2), IL-2, IL-10, IL-6 and IL-23 (figure 6B) (Brown 
2006), (LeibundGut-Landmann, Gross et al. 2007). 
DECTIN-1 signaling involves the spleen tyrosine kinase (SYK) leading to 
downstream signaling through caspase-recruitment domain 9 (CARD9) (Brown 
2006). The CARD9 pathway has been reported recently to induce DC 
maturation and direct T helper 17 (Th17)-cell responses (LeibundGut-
Landmann, Gross et al. 2007; Gross, Gewies et al. 2006). This response is 
independent of Toll like receptors, but there are also other DECTIN-1-mediated 
A B 
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responses like the production of pro-inflammatory cytokines and chemokines 
which require collaborative signaling from TLR (figure 6B) (Brown 2006). 
 
1.4.3) C-type lectin-like receptor-2 (CLEC-2) 
 
Human CLEC-2 has been identified to be a novel activating receptor that is 
expressed on the surface of platelets and megakaryocytes (Suzuki-Inoue, Fuller 
et al. 2006) and responsible for platelet activation by the snake toxin rhodocytin 
(Suzuki-Inoue, Fuller et al. 2006). 
As for other members of the C-type lectin-like family of receptors, its putative 
carbohydrate-recognition domain lacks the key structural features that confer 
binding to carbohydrates, suggesting that its endogenous ligand may be a 
protein. Recently, crystallized CLEC-2 was shown to have a compact C-type 
lectin-like domain with a flexible loop on its surface which has been suggested 
to play an important role in ligand binding (Watson, Brown et al. 2007). 
Additionally, CLEC-2 has been reported to facilitate the capture of HIV-1 by 
CLEC-2-transfected HEK293 cells and platelets. However, CLEC-2 does not 
bind to a viral envelope protein but to a cell surface protein derived from the 
host HEK293 cell (later identified to be podoplanin) integrated into the viral 
envelope upon budding (Chaipan, Soilleux et al. 2006). In line with these 
findings, several studies have identified podoplanin on tumour cells, as an 
endogenous ligand for CLEC-2 (Suzuki-Inoue, Kato et al. 2007; Christou, 
Pearce et al. 2008). The interaction between CLEC-2 on platelets and 
podoplanin on tumour cells has been shown to be essential for the platelet 
aggregation-inducing activity of tumour cells. Therefore it was proposed that the 
interaction between podoplanin and CLEC-2 may regulate tumour metastasis 
and nestling, the former by covering tumour cells with platelets and thereby 
hiding it from detection by the immune system and the latter by activating 
platelets to release growth factors important in angiogenesis and tumour growth 
(Kato, Fujita et al. 2003; Kato, Kaneko et al. 2008).   
The CLEC-2 signaling cascade is initiated by a single YXXL (Tyr-Xaa-Xaa-Leu) 
motif in its cytoplasmic domain (Fuller, Williams et al. 2007). As previously 
reported for DECTIN-1 (Brown 2006), cross-linking of CLEC-2 induces Src 
kinase-dependent tyrosine phosphorylation of the YXXL sequence, resulting in 
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the activation of the tyrosine kinase SYK and initiation of a signaling pathway 
that culminates in activation of phospholipase Cγ2 (PLCγ2) (Fuller, Williams et 
al. 2007). 
 
1.4.4) C-type lectin-like receptor-1 (CLEC-1) 
 
CLEC-1 transcripts could be detected in endothelial, dendritic and monocytic 
cells (Colonna, Samaridis et al. 2000; Sobanov, Bernreiter et al. 2001). 
Although it shows high similarity in structure and sequence to the other myeloid 
subfamily members of the NK gene complex, neither ligands nor functions could 
yet be assigned to CLEC-1. Interestingly, as described in this work CLEC-1 
does not show surface expression on any cell type tested, therefore it might be 
possible that the endogenous location of CLEC-1 is to be found in intracellular 
membranes rather that on the cell surface, like it is the case for intracellular 
TLR.  
Endothelial cells are known to contain CLEC-1 mRNA, although at first sight it 
seems gratuitous for this cell type to express a member of a receptor family 
having primarily immune functions. Nevertheless endothelial cells also express 
LOX-1, a highly homologous family member of CLEC-1, which is known to be of 
high importance in the formation of atherosclerositic plaques upon binding to its 
most prominent ligand oxLDL (Chen, Kakutani et al. 2000; Mehta, Sanada et al. 
2007). 
Endothelial cells form a thin cell layer at the interior surface of blood vessels, 
providing an interface between circulating blood and surrounding vessel. 
Nevertheless, they are much more than mere lining cells having a diverse array 
of functions in vascular biology and immunology. Endothelial cells are essential 
in the control of blood pressure, blood clotting and angiogenesis, as well as in 
immunology e.g. in controlling inflammation in response to histamines or in 
diapedesis of immune cells (Dejana 2004). Immune cell diapedesis through 
blood vessel endothelium is an essential process underlying most innate and 
adaptive immune responses and is defined by leukocyte adhesion to the 
endothelial cells, squeezing through the space between between two adjacent 
endothelial cells and infiltration into the underlying tissue (Muller 2003).  
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Furthermore, endothelial cells have been shown to express Toll like receptors 
and therefore are able to directly bind and react to pathogenic patterns 
(Maaser, Heidemann et al. 2004) (Hijiya, Miyake et al. 2002). All these facts 
clearly show the importance of endothelial cells in immunity and therefore it 
might indeed be possible that CLEC-1 serves an important function in this cell 
type.  
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1.5) Eukaryotic and prokaryotic Pathogens  
 
The main task for the immune system is to detect and destroy invading 
pathogens of any kind. Cells of the innate immune system such as dendritic 
cells, monocytes and macrophages sense pathogens via their various pattern 
recognition receptors leading to a cascade of immune reactions to finally clear 
the infection.  
Pathogens on the other hand have developed a wide range of immune evasion 
strategies to avoid detection by the immune system. Obligate intracellular 
pathogens are either able to resist killing inside phagocytic cells or even actively 
invade non-phagocytic cells. Once having avoided destruction by lysosomal 
enzymes, the intracellular environment protects the pathogen not only against 
defence mechanisms of the immune system but also against drugs 
administered as therapy.  
 
1.5.1) Toxoplasma gondii 
 
Toxoplasma gondii is an ubiquitous protozoan parasite that requires an 
intracellular site for growth and replication and causes toxoplasmosis in animals 
and humans. Although the definite host of T. gondii, where it can conclude the 
sexual part of its life cycle, are felines, the asexual part of the cycle can take 
place in any warm-blooded animal as depicted in figure 7A. 
The invasive form of the parasite shown in figure 7B is the motile haploid 
tachyzoite, which is rapidly dividing and can infect a wide range of mammalian 
host cells including immune and non-immune cells (Kim and Weiss 2004). 
Inside the cell the parasite propagates by a series of binary fissions, finally 
causing the infected cell to burst and to release the tachyzoites into the 
surrounding environment (Dubey 2002). There the haploid tachyzoites 
reversibly transform into latent bradyzoites to produce tissue cysts mainly in 
brain and muscle tissue (McCabe and Remington 1988). If tissue cysts are 
taken up by felines the parasites infect epithelial cells of the small intestine 
where they undergo sexual reproduction and oocyst formation. Oocysts are 
then shed with the feces and can be taken up by intermediate hosts again.  
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A B 
  
Figure 7: The Toxoplasma gondii life cycle. A: Schematic overview showing the asexual and 
sexual part of the Toxoplasma gondii life cycle. Toxoplasma gondii is able to infect any warm-
blooded animal, were it forms tissue cysts taken up by further hosts with food. If taken up by 
felines, Toxoplasma gondii can complete the sexual part of its life cycle and form oocysts. B: T. 
gondii tachyzoite invading a HeLa cell (HC). AC: apical cytoskeleton, PVM: parasitophorous 
vacuole membrane, MJ: moving junction, where the invasion is thought to be driven by parasite 
motors. scale bar represents 0.5 µm. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Microbiology (Boothroyd and Dubremetz 2008), copyright (2008) and from Trends 
in Microbiology, 6, Jean François Dubremetz, “Host cell invasion by Toxoplasma gondii”, 4, 
Copyright (1998) (Dubremetz 1998), with permission from Elsevier. 
 
The invasive process of the parasite into the host cell involves cellular 
recognition and adhesion, secretion of penetrating enhancing factors (PEF), 
conoid penetration and finally the induction of a parasitophorous vacuole, a 
protective and exchange site. This invasion process is an active, oriented and 
specific process (Bonhomme, Pingret et al. 1992). The central role of the 
parasitophorous vacuole is to act as the interface between the parasite and its 
immediate environment the host cytoplasm, functioning in structural 
organization, nutrient acquisitions and signaling (Sinai 2008).  
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1.5.2) Listeria monocytogenes 
 
Listeria monocytogenes are gram-positive rod-shaped bacilli and the 
causative agent of listeriosis, a rare but lethal food-borne infection 
characterized by meningitis, meningo-encephalitis, materno-fetal and 
perinatal infections. 
 
 
Figure 8: Listeria monocytogenes 
cell infection process. 
Electron-micrographs and 
schematic representation of the 
successive steps of cell infection by 
L.monocytogenes. a. 
L.monocytogenes induces its entry 
into a cell using InlA, B 
(InternalinA,B). b. Bacteria are 
internalized in a phagosome. c, d. 
membrane of the vacuole is 
disrupted by secretion of PlcA and 
PlcB (phosphatidylinositol-specific 
phospholipase A/B) and the pore-
forming toxin LLO (listeriolysin O). 
Bacteria are released into the 
cytoplasm, where they multiply and 
polymerize actin. e. Bacteria enter 
neighbouring cells by forming 
protrusions in the plasma 
membrane. f. On entry into the 
neighbouring cell, bacteria are 
present in a double-membraned 
vacuole. F-actin, filamentous actin.  
Reprinted by permission from 
Macmillan Publishers Ltd: Nature 
Reviews Microbiology (Boothroyd 
and Dubremetz 2008) copyright 
(2006) and (Cossart and Lecuit 
1998) copyright (1998) and from 
Cell, 68/3, C. Kocks et. al., “L. 
monocytogenes-induced actin 
assembly requires the actA gene 
product, a surface protein”, 11, 
Copyright (1998), with permission 
from Elsevier (Kocks, Gouin et al. 
1992).  
 
 
After crossing the intestinal barrier the bacteria reach the liver via lymph and 
blood, where they replicate in hepatocytes. They can also cross the blood-
brain barrier and the materno-fetal barrier and reach the brain and the 
placenta, respectively. Listeria monocytogenes is able to resist intracellular 
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killing when phagocytosed by macrophages and to invade many types of 
cells, which are normally non-phagocytic. 
L.monocytogenes enters non-phagocytic cells and can spread from cell to 
cell (Pizarro-Cerda and Cossart 2006; Cossart and Sansonetti 2004; Cossart, 
Pizarro-Cerda et al. 2003) by the “zipper mechanism” which involves the 
progressive interaction of bacterial surface ligands with their respective 
cellular receptors to form a tight apposition of the plasma membrane around 
the incoming microbe (figure 8).  
After entry into cells, the bacteria are entrapped into a vacuole from which they 
escape into the cytosol where they replicate and recruit actin. They polymerize 
actin at one pole of the bacteria and the resulting network of branched 
filaments is used to propel bacteria to move through the cytoplasm. At the 
plasma membrane, bacteria push the membrane and induce the formation of 
protrusions which invade neighboring cells and generate a two membrane 
vacuole from which bacteria escape, allowing a new cycle of replication to 
take place in a second infected cell. 
The major bacterial genes and factors critical for the cell infection process 
include internalin A (InlA) and InlB for the entry process (Bierne, Sabet et al. 
2007) and the pore-forming toxin LLO for the escape from the vacuole 
(Hamon, Batsche et al. 2007; Lecuit, Sonnenburg et al. 2007), whereas the 
actin-based motility is mediated by the surface protein ActA (Gouin, Welch et 
al. 2005).  
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1.6) Aims 
 
CLEC-1 and CLEC-2 are C-type lectin-like receptors encoded in the myeloid 
subfamily region of the human NK gene complex. Like other receptors of this 
subfamily, they are expressed on cells of the myeloid lineage rather than on NK 
cells. Considering their homology to two other closely related members of the 
subfamily, LOX-1 and DECTIN-1, which function as innate pattern recognition 
receptors, a similarly important function can be predicted for CLEC-1 and 
CLEC-2. 
 
A general aim of this study was to investigate the distribution of CLEC-1 and 
CLEC-2 expression in different subtypes of human peripheral blood leukocytes 
and to find indications about potential functions of both receptors. Furthermore, 
the genomic regions of the murine and human myeloid subfamilies were 
investigated in regard to their evolutinary relationship and to identify additional 
related genes.  
 
Specific aims of this study were:  
 
• to analyse the expression of CLEC-1 and CLEC-2 in subsets of human 
peripheral blood cells. 
• to study possible functional implications of CLEC-1 and CLEC-2 
expression. 
• to perform a comparative analysis of the murine and human genomic 
regions containing the myeloid subfamily of the NK gene complex. 
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2) Materials and methods 
 
2.1) Electrophoresis  
 
Agarose gel electrophoresis 
The required volume of the DNA sample was mixed with 6x loading buffer 
(Fermentas International, Canada) and loaded onto a 1% agarose gel. The 
DNA was directly stained during separation by adding ethidium bromide to the 
gel. The separation was done by applying 70V for 30min. As a molecular weight 
standard marker a GeneRuler 123bp DNA ladder (Fermentas, Germany). Tris-
acetate-EDTA (TAE)-buffer (Invitrogen Life Technologies, Austria) was used for 
the preparation of the gel and as electrophoreses buffer. 
 
SDS polyacrylamide gel electrophoresis 
1x105 Cells were lysed in 10µl 4x sodium dodecyl sulphate (SDS) sample buffer 
and  three times frozen in liquid nitrogen and heated to 95°C.  
The samples were then loaded onto the polyacrylamide gel and electrophoresis 
was carried out in the presence of 1xSDS electrophoresis buffer (Appendix A) 
at the appropriate current and voltage. As marker a Low Molecular Weight 
Marker (14,4 – 97kDa) (GE Healthcare Europe, Germany) was used.  
 
2.2) Western blotting 
 
After SDS polyacrylamid gel electrophoresis proteins were transferred to 
Immobilon polyvinylidene fluoride (PVDF) membranes (Millipore / Biomedica 
Medizinprodukte, Austria) by semi-dry blotting (PeqLab Biotechnology, 
Germany) at 350 mA for 1,5 h. The transferred proteins could be visualized by 
staining the membrane with PonceauS staining solution (SERVA 
Electrophoreses, Germany). 
Membranes were incubated in blocking buffer (Appendix A) for 30min at room 
temperature. Primary antibodies were diluted in blocking buffer as 
recommended by the company (see table below) and incubated for 1h at room 
temperature or over night at 4°C on a shaker. Membranes were then washed 
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three times for 5 min with 1% Tween in PBS+ (PBS+T). Secondary antibodies 
labeled with horse radish peroxidase (HRP) were diluted in PBS+T as 
recommended by the company (see table below) and added to the membranes 
for at least 1 hour at room temperature followed by washing steps as described 
above. Afterwards the membranes were incubated with LumiGlo Reagents (Cell 
Signaling Technology, USA) as recommended in the company’s protocol. 
Signals were detected by exposing a film (Fujifilm, Germany) to the membranes 
and thereafter the films were developed using the film developer Curix60 (Agfa 
HealthCare, Austria).  
If membranes needed to be stained with another antibody they were incubated 
for 20min at 50°C in prewarmed stripping buffer (Appendix A). Then the 
membranes were washed three times for 5 min with PBS+T. Afterwards the 
antibody staining procedure was carried out as described above. 
 
Primary antibodies used for Western blotting 
antibody company 
working 
concentration / 
dilution 
mouse anti-human CLEC-1  
mouse anti-human CLEC-2  R&D Systems, USA 0,3µg/ml 
mouse anti-human COX-1 
mouse anti-human 
Nucleoporin 
kindly provided by Dr. 
Wolfgang Gregor (Veterinary 
University Vienna) 
1:3000 
rabbit anti-human LAMP-1  Santa Cruz Biotechnology, 
USA 1:500 
mouse anti-human Calnexin  Abcam, USA 1:4000 
Secondary antibodies used for Western blotting 
sheep anti-mouse Ig, HRP-
linked 
sheep anti-rabbit Ig, HRP-
linked 
GE Healthcare Europe, 
Germany 1:6000 
 
-33- 
2.3) Cell culture techniques 
 
Maintenance of cells 
Human fibroblasts GM5520 used for Toxoplasma gondii amplification were 
grown in Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher Scientific, 
USA) with 10% foetal calf serum (FCS, Lonza, Germany), 10 mM L-Glutamine 
(Sigma-Aldrich, UK) and 5ml/500ml Penicillin/Streptomycin mixture (10.000U/ml 
Penicillin / 10.000U/ml Streptomycin, Lonza, Germany) in a 5% CO2 
atmosphere at 37°C.  
The human breast cancer cell line MCF-7 stably transfected to express 
podoplanin (kindly provided by Prof. Michael Detmar, ETH Zürich) was grown 
in DMEM with 10% FCS, 10mM L-Glutamine and 5ml/500ml 
Penicillin/Streptomycin mixture, 60 µg/ml Hygromycin B (Invitrogen Life 
Technologies, Austria) and 150 µg/ml G418 (Gibco Invitrogen Corporation, 
Austria) in a 5% CO2 atmosphere at 37°C. 
Human embryonic kidney (HEK) 293 cells used for adenovirus amplifications 
were grown in Minimum Essential Medium Alpha (MEM alpha, Gibco Invitrogen 
Corporation, Austria) supplemented with 10% newborn calf serum (NCS, Fisher 
Scientific, Austria), 10mM L-Glutamine and 5ml/500ml penicillin/streptomycin 
mixture in a 5% CO2 atmosphere at 37°C.  
Primary human umbilical vascular endothelial cells (HUVEC) were grown in 
M199 medium (Lonza, Germany) supplemented with 20% foetal calf serum, 
2ml/500ml endothelial cell growth supplement (ECGS, PromoCell/ Biomedica 
Medizinprodukte, Austria), 2U/ml Heparin (Roche Diagnostics, Germany) und 
10ml/500ml PSFG (Penicillin 10.000U/ml, Streptomycin 10mg/ml, Fungizon, 
200mmol Glutamin, Lonza, Germany) in a 5% CO2 atmosphere at 37°C. Human 
cords were obtained from the Lainzer Hospital (Vienna) and HUVEC were 
isolated and cultured as described (Sobanov, Bernreiter et al. 2001). 
All adherent cells were passaged by treatment with Trypsin (Gibco Invitrogen 
Corporation, Austria) after washing two times with 1xPBS.  
Suspension cell lines used: 721.221, Mono-Mac-6, K-562, Jurkat, U-937, 
CCRF-CEM, P815, NK-92, RPMI-8866 were all grown in RPMI1640 medium 
containing 10% FCS, 10mM L-Glutamine and 5ml/500ml penicillin/streptomycin 
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mixture in a 5% CO2 atmosphere at 37°C. NK-92 cultures were supplemented 
in addition with 1mM sodium pyruvate, 50mM β-mercaptoethanol (Sigma-
Aldrich, UK) and human rIL-2 (R&D Systems, USA) at a final concentration of 
20 IU/ml.  
 
Toxoplasma gondii RH (kindly provided by Prof. John Trowsdale, University of 
Cambridge) was amplified by infection of the human GM5520 fibroblast cell line. 
The parasites were isolated from 100% infected GM5520 by scraping the cell 
monolayer and centrifugation at 500xg for 10min. The resuspended cell pellet 
was aspirated three times through a 20 g needle and another three times trough 
an 18 g needle. The suspension was filtered through a 3µm filter (Nuclepore 
Whatman, UK) and centrifuged again for 10min at 500xg. The pellet containing 
the isolated parasites was resuspended and used further for infection of cells at 
a multiplicity of infection (MOI) of 10 and for flow cytometry analysis. 
 
Listeria monocytogenes LLO- (kindly provided by Prof. Thomas Decker, 
University of Vienna) were grown on BHI (brain heart infusion) agar plates and 
one colony was used to prepare a 5ml over night culture. Density of bacteria 
was determined by measuring OD600 and used immediately for FACS analysis 
or to infect HUVEC at a MOI of 100 for 2h at 37°C. 
 
Isolation of PBMC and CBMC 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque 
PLUS (GE Healthcare Europe, Germany) gradient centrifugation according to 
the manufacturer’s instructions. Venous peripheral blood was obtained from 
healthy volunteers or purchased from the Red Cross, cord blood was kindly 
provided by Anita Jandrositz/Prof. Karl-Heinz Preisegger, EccoCell, Austria.  
For subsequent assays either whole PBMC or positively isolated subsets 
(CD14+, CD3+, CD19+) were used as described in 2.3.5. 
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Isolation of platelets 
Whole blood was centrifuged for 15min at 800rpm to separate blood cells from 
serum. Serum was collected and centrifuged at 3000rpm for 10min to pellet 
platelets. Platelets were washed two times and processed immediately for flow 
cytometry staining, RNA isolation or Western blotting. 
 
Isolation of granulocytes 
Granulocytes were isolated using the pellet resulting from Ficoll-Paque PLUS 
(GE Healthcare Europe, Germany) gradient centrifugation as described in 2.3.2. 
After removal of Ficollsupernatant and three times washing of the granulocyte-
erythrocyte mixture at 1200rpm for 5min, the pellet was incubated with NH4Cl 
buffer (Appendix A) for 10 min at 4°C to lyse erythrocytes. After washing the 
lyses step was repeated a second time. Granulocytes were processed 
immediately for RNA isolation, flow cytometry staining or Western blotting or 
maintained in RPMI1640 medium for a maximum of one day. 
 
Positive isolation of PBMC and CBMC subsets 
CD14+, CD3+ and CD19+ subsets of PBMC were isolated using the respective 
magnetic cell sorting (MACS) positive isolation kits (Milteny Biotech, Germany) 
according to the manufacturer’s instructions and processed immediately for flow 
cytometry staining, RNA isolation or Western blotting or kept in RPMI1640 
medium over night.  
CD34+ progenitor cells were isolated from cord blood mononuclear cells using 
the MACS CD34+ cell isolation kit (Milteny Biotech, Germany) and expanded in 
RPMI1640 medium supplemented with stem cell factor (SCF, 50ng/ml; 
ImmunoTools, Germany), FMS-like tyrosine kinase 3-ligand (Flt3-L, 50ng/ml; 
ImmunoTools, Germany) and Thrombopoietin (TPO, 50ng/ml; Peprotech, UK) 
for three days. 
 
Differentiation of CD34+ cells to cord blood derived dendritic cells 
Cord blood derived dendritic cells were prepared as described (Sobanov, 
Bernreiter et al. 2001). In short; after expansion for three days as described in 
2.3.5, differentiation was induced in the presence of 100ng/ml granulocyte-
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macrophage colony-stimulating factor (GM-SCF, Peprotech, UK), 50ng/ml Flt3-
L (Peprotech, UK), 2,5ng/ml TNF-α (R&D Systems, USA), 20ng/ml stem cell 
factor (SCF, Peprotech, UK), 25ng/ml Interleukin-4 (IL-4, Peprotech, UK) for 6 
to 9 days. Medium was changed every third day. 
 
Infection of cells with adenoviruses and pathogens 
Adherent cells were infected at a MOI of 100 by adding the virus to the usual 
growth medium and incubating the cells for 48h. For infection of suspension 
cells virus was pre-incubated in serum free medium with 0,2µM LnCl3 (Palmer, 
Stoddart et al. 2008) and added to the cells at a MOI of 10.000.  
For infection with Listeria monocytogenes and Toxoplasma gondii HUVEC were 
seeded the day before infection and incubated with isolated Listeria 
monocytogenes at a MOI of 100 and with isolated Toxoplasma gondii at a MOI 
of 10 for two days.  
 
Stimulation of cells 
Cordblood derived dendritic cells (CBDC) and HUVEC were incubated with 1µM 
CpG-ODN M362 (sequence: 5’-tcg tcg tcg ttc gaa cga cgt tga t-3’, from 
InvivoGen, France), 1µM control-ODN M362 (sequence: 5’- tgc tgc tgc ttg caa 
gca gct tga t-3’, from InvivoGen, France), 25µg/ml poly(I:C) (InvivoGen, 
France), 10µg/ml Imiquimod (InvivoGen, France), 100ng/ml LPS (Sigma-
Aldrich, UK), 10ng/ml TNFα (R&D Systems, USA), 1 µg/ml phorbol myristate 
acetate (PMA, Sigma-Aldrich, UK) at the respective usual growth conditions for 
the indicated durations.  
CBDC kindly provided by Dr. Frank Kalthoff (Novartis, Austria) were stimulated 
for maturation with 100 ng/ml LPS (Sigma-Aldrich, UK), 4 µg/ml of anti-CD40 
mAb (mAb clone 626.2) cross-linked in solution by the addition of 2 µg/ml of 
F(ab')2-fragments of goat-anti mouse IgG (Pierce Chemical, USA), 25 µg/ml 
Zymosan A (Sigma-Aldrich, UK) or 10 ng/ml IFNγ for 6 hours at the usual 
growth conditions.  
Stimulation of the cells was verified by Real-Time RT-PCR showing the 
upregulation of E-Selectin mRNA in HUVEC and CCL22 (chemokine (C-C 
motif) ligand 22) mRNA in dendritic cells by Real-Time RT-PCR. After 
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stimulation and infection the cells were washed thoroughly and processed for 
flow cytometry analysis, immunofluorescence staining or RNA isolation and 
subsequent cDNA synthesis for Real-Time RT-PCR. 
 
Adhesion assay 
Adhesion assays were performed to show binding of CLEC-2 expressing cells 
to podoplanin expressing cells. Adherent cells were incubated with DiO-labeled 
(Molecular Probes, USA) suspension cells on a shaker for 30min (15min 
horizontal, 15min vertical shaking) at 37°C in a 5% CO2 atmosphere using the 
growth medium appropriate for the adherent cells. Cells were washed 
thoroughly, detached by trypsinization and analysed by flow cytometry. 
Adherent cells used were MCF-7 with or without podoplanin (kindly provided by 
Michael Detmar, ETH Zürich), HUVEC and LEC-TERT (TERT (Telomerase 
Reverse Transcriptase)-immortalized Lymphatic endothelial cells, kindly 
provided by Heide Niederleithner/Peter Petzelbauer, Medical University Vienna, 
Austria). Suspension cells used were PBMC, CD14+ monocytes, CD3+ 
lymphocytes, CD19+ lymphocytes, granulocytes, platelets and K-562 as well as 
several other suspension cell lines. K-562 infected with AdVCLEC-2 were used 
as positive control for the adhesion of CLEC-2 expressing cells to podoplanin 
expressing cells. 
 
Immunofluorescence staining 
Endothelial cells were seeded in chamber slides (Lab-Tek, Nunc, Germany) 
and infected with the respective adenovirus or pathogen as described in 2.5.4 
the next day. If applicable cells were stimulated as described in 2.6, washed, 
fixed for 15 min with 4% paraformaldehyd (Sigma-Aldrich, UK) and optionally 
permeabilized for 15 min with 0,5% TritonX (Sigma-Aldrich, UK).  
Cord blood derived dendritic cells were infected with the respective adenovirus 
as described in 2.5.4 and stimulated as described in 2.6. After washing cells 
were put on ice and incubated with 2 µl Fc-blocking solution (Miltenyi Biotech, 
Germany) per 1x106 cells for 20min.  Afterwards cells were attached to 
adhesion slides (Marienfeld, laboratory glassware, Germany) according to the 
manufacturer’s instructions. Fixation and permeabilization was achieved by 
incubation with ice cold methanol for 30min. Following fixation and 
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permeabilization endothelial and dendritic cells were incubated with 5% FCS in 
PBS for 15min on ice. Primary antibodies and, after two washing steps, 
secondary antibodies were added to the cells at the concentrations 
recommended by the manufacturer (see table below) for 30 min at 4°C. To 
visualize the nuclei, cells were stained in addition with the fluorescent DNA dye 
4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, UK) for 15 min before 
mounting the slide.  
Results were analyzed in a Nikon Diaphot TMD fluorescence microscope 
(Nikon, UK). 
 
 
Primary antibodies used for immunofluorescence staining 
antibody company working concentration / dilution 
mouse anti-human CLEC-1  
mouse anti-human CLEC-2  
mouse anti-human DECTIN-1 
mouse IgG2b isotype control 
R&D Systems, 
USA 1µg/ml 
mouse anti-human Golgin-97 Molecular 
probes, USA 1:200 
mouse anti-human Calnexin Abcam, USA 1:100 
Secondary antibodies used for immunofluorescence staining 
goat anti-mouse IgG-AlexaFluor 
488 
Molecular 
probes, USA 1:500 
rabbit anti-mouse IgG-FITC 
F(ab)2 Dako, Denmark 1:100 
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2.4) Adenovirus techniques 
 
Generation of primary adenoviruses 
cDNA of CLEC-1, CLEC-2 and DECTIN-1 was subcloned into the pAC 
CMVplpASR(+), shuttle vector (Gomez-Foix, Coats et al. 1992) and the 
resulting vectors and the adenoviral backbone vector pJM17 (McGrory, Bautista 
et al. 1988) were co-transfected into HEK293 cells by Ca3(PO4)2-precipitation 
using the Mammalian Transfection Kit (Biomedica, Austria) according to the 
manufacturer’s instructions. After the formation of plaques, adenovirus clones 
were isolated by a three times freeze-thaw lysing cycle and centrifuging the 
HEK293 cells as described before (Gomez-Foix, Coats et al. 1992). 
pAC-DR1: DECTIN-1 with C-terminal FLAG-Tag between EcoR I and Xba I 
cutting sites in expression vector pAC CMVpLpA SR(+). 
pAC-CR1: CLEC-1 with C-terminal FLAG-Tag between EcoR I and Xba I 
cutting sites in expression vector pAC CMVpLpA SR(+). 
pAC-CLEC2: CLEC-2 between EcoR I and Xho I cutting sites in expression 
vector pAC CMVpLpA SR(+). 
 
Selection and amplification of monoclonal adenoviruses 
Monoclonal adenoviruses were isolated by infecting HEK293 cells in a 96 well 
plate with serial dilutions of the primary adenovirus isolate. Wells containing one 
single plaque after 5-7 days of incubation were selected and the adenovirus 
clones were isolated by harvesting the cells and lysing them by a three times 
freeze-thaw cycle in HE-buffer (Appendix A). Monoclonal adenoviruses were 
amplified by infection and lyses of increasing amounts of cells. 
 
Purification of adenoviruses 
A highly concentrated adenovirus suspension, resulting from harvesting the 
adenoviruses from 40 T175 cell culture flasks of infected cells, was centrifuged 
two times over a CsCl-gradient. The first centrifugation step was done at 20°C 
with 48.000 rpm for 1 hour and the second step with 55.000 rpm over night.  
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The purified virus was collected and dialysed for 4 hours at 4°C to remove the 
remaining CsCl. After 4 hours the dialysis buffer (Appendix A) was changed and 
the dialysis was continued over night at 4°C.  
 
2.5) Flow cytometry 
 
Cells were washed and adjusted to 3x105 cells per 50 µl sample and incubated 
with 2 µl FcR-blocking solution (Miltenyi Biotech, Germany) or 5% FCS for 15 
min. Primary antibody was added using the concentration recommended by the 
manufacturer (see table below) and incubated for 30 min on ice. Samples were 
washed and incubated for another 30 min with the appropriate secondary 
antibody at the recommended concentrations (see table below). After a final 
washing step, cells were fixed and FACS analysis was performed with a BD 
FACSCalibur.  
Binding of flag-tagged soluble CLEC-1 and DECTIN-1 (kindly provided by Mag. 
Irene Michl, Medical University Vienna, Austria) was tested after blocking by 
incubation of 2 µg / 50 µl soluble protein for 1,5 hour at 4°C with the cells in 
question and detection of the bound protein by FITC-labeled anti-FLAG 
antibody. 
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Primary antibodies used for flow cytometry 
antibody company working concentration / dilution 
mouse anti-human CLEC-1  
mouse anti-human CLEC-2  
mouse anti-human DECTIN-1 
mouse IgG2b isotype control 
R&D Systems; 
USA 1µg/50µl 
mouse anti-human CD15 PE-
conjugate  
mouse anti-human CD3 APC-
conjugate  
mouse anti-human CD14 FITC-
conjugate  
mouse anti-human CD11b PE-
conjugate  
mouse anti-human CD1a APC-
conjugate  
mouse anti-human CD19 PE-
conjugate  
mouse IgG isotype control PE-
conjugate  
mouse IgG isotype control APC-
conjugate  
mouse IgG isotype control FITC-
conjugate  
Miltenyi Biotech, 
Germany 0,25µg/50µl 
mouse anti-FLAG M2 FITC 
conjugate  
Sigma-Aldrich, 
UK 0,25µg/50µl 
Secondary antibodies used for flow cytometry 
rabbit anti-mouse IgG-FITC F(ab)2 Dako, Denmark 1:100 
 
2.6) Subcellular fractionation 
 
Cells were harvested in Et3N buffer (Appendix A) with Complete Protease 
Inhibitor Cocktail (Roche Diagnostics, Germany) and lysed in a Potter 
homogenizer until cells were broken. The raw homogenate was centrifuged at 
2900 rpm for 10 min. Supernatant 1 was centrifuged again at 3500 rpm at 10 
min and pellet 2 was added to pellet 1. Both pellets were resuspended in 5 ml 
2,2 M sucrose and centrifuged at 24000 rpm for 80 min to purify nuclei from 
mitochondria and to obtain the final nuclear fraction. Supernatant 2 was 
centrifuged at 9000 rpm for 15 min. Pellet 3 was washed and centrifuged a 
second time like before to obtain the final mitochondrial fraction. Supernatant 3 
was centrifuged at 13000 rpm for 15 min. The resulting pellet 4 was 
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resuspended and centrifuged a second time to obtain the final lysosomal 
fraction. Supernatant 4 was centrifuged at 39000 rpm for 40 min. Supernatant 5 
contained the cytosolic fraction and pellet 5 was resuspended and repelletet to 
obtain the final microsomal fraction.  
 
2.7) RNA techniques and Real-Time RT-PCR  
 
After incubation with the indicated stimulating agents, adherent cells were 
treated with RNAlater (Ambion, USA), washed once with DEPC-treated water, 
lysed in 1ml Trizol (Invitrogen, Austria) per 1x106 cells and processed for RNA 
isolation.  
Suspension cells were pelleted and directly lysed in 1ml Trizol per 1x106 cells. 
RNA was isolated by chloroform extraction and subsequent precipitation using 
Isopropanol. 2 µg of total RNA were reverse transcribed into cDNA using 
SuperscriptTM II RT (Invitrogen, Austria) and oligo-dT primers (Applied 
Biosystems, USA) according to the manufacturer's protocol.  
To monitor gene expression Real-Time RT-PCR was performed using a Light 
Cycler instrument and the Fast Start DNA-Mastermix SybrGreen1 (Roche 
Diagnostics, Germany) according to established procedures (Brostjan, Bellon et 
al. 2002). As internal standard for normalization β2-microglobulin or β-actin 
mRNA was used. Quantification and standardization was performed as 
described (Brostjan, Bellon et al. 2002). Briefly, linearized plasmids containing 
the genes of interest were used as standards. A standard dilution series of the 
plasmids was performed for every gene of interest. Since standard samples 
were based on pure preparations of plasmid DNA fragments rather than total 
cDNA mixtures, test dilution series of plasmids in water as well as in PBMC 
cDNA were performed to verify that the sensitivity of the Real-Time RT-PCR 
assay was not affected by the presence of unrelated cDNA molecules. The 
oligonucleotide primers used (obtained from Invitrogen GmbH, Austria) were as 
follows. 
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oligonucleotide primer sequence from 5’ end 
ß2microglobulin-forward GATGAGTATGCCTGCCGTGTG 
ß2microglobulin-reverse CAATCCAAATGCGGCATCT 
DECTIN-1-forward ACCATGGGGGTTCTTTCC 
DECTIN1-reverse CCATGGTACCTCAGTCTG 
CLEC-1-forward GGGGGCTTTTGTTTTTTC 
CLEC-1-reverse GCTTTGTTATACAGCTCACG 
CLEC-2-forward GGATTTGGTCTGTCATGC 
CLEC-2-reverse GCAGTACTGCTTACTCTC 
Actin-forward GTGATGGTGGGCATGGGTCA 
Actin-reverse TTAATGTCACGCACGATTTCCC 
LOX-1-forward GCATGCAATTATCCCAGG 
LOX-1-reverse GCTACTCTCTTCAGTGTTT 
CLEC9a-forward TGGAGCATTTGGCACACCAG 
CLEC9a-reverse CAACCCCACCCAGTAATCATAGC 
GABARAPL1-forward TGTCAACAACACCATCCCTCC 
GABARAPL1-reverse CTTCCAACCACTCATTTCCCATAG 
CLEC12b-CTLD1-forward TGAGGAGAAAACCTGGGCTA 
CLEC12b-CTLD2-reverse GCCAGAGGAGTCCCATGATA 
CLEC12b-deletion-stalk-forward TGGGGATGATGTTTTTGCAG 
CLEC12b-isertion-CTLD2-reverse TCCATGGAAAGCTTGTGTTT 
CLEC-2-complete-forward GCAAAGTCATTGAACTCTGAGC 
CLEC2-complete-reverse TCCTGTCCACCTCTTTGCAT 
CLEC9a-complete-forward ATGCACGAGGAAGAAATATACAC 
CLEC9a-complete-reverse TCAGACAGAGGATCTCAACGC 
CCL22 s CGCGTGGTGAAACACTTCTA 
CCL22 as ATAATGGCAGGGAGGTAGGG 
E-Selectin LP CGCTGTAAAATCTTGGCACA 
E-Selectin RP CTGTGGGCATTCAACATCTG 
Plasmids used for standardization source 
pZErO-DECTIN-1 
pZErO-CLEC-1 described previously (Sobanov 2001) 
pZErO-CLEC12b  clone IRAKp961A2448Q2 (RZPD, Germany) 
pZErO-FLJ31166 clone HU3_p983D11229D2 (RZPD, Germany) 
pZErO-GABARAPL1  clone IRATp970E1244D6 (RZPD, Germany) 
pZErO-CLEC-2 
pZErO-CLEC-9a 
PBMC cDNA amplified by RT-PCR using CLEC-
2complete-forward, CLEC2-complete-reverse 
and CLEC9a-complete-forward, CLEC9a-
complete-reverse, respectively and cloned into 
pZErO-2 (Invitrogen, The Netherlands) 
 
-44- 
2.8) Bioinformatics  
 
Search for additional genes and homologs of known genes 
Novel genes were searched for by comparing sequences available from the 
UCSC Genome Browser (available at: http://genome.ucsc.edu/) and the NCBI 
(National Center for Biotechnology Information) Map Viewer (available at: 
www.ncbi.nlm.nih.gov/mapview). The human reference sequence (human 
assembly may 2004, hg17) is based on NCBI Build 35 and was produced by 
the International Human Genome Sequencing Consortium. Mouse genome 
data (mouse assembly march 2005, mm6) was obtained from the build 34 
assembly by NCBI. Sequences of other species (Pan troglodytes: panTro2, 
Rhesus macaques: rheMac2, Bos taurus bosTau4, Canis familiaris: canFam2) 
were also obtained from UCSC Genome Browser and NCBI Map Viewer. For 
the search of genes already known in one species (e.g. NKG2i in mice) the 
NCBI BLAST (blastn) algorithm was used (available at: 
http://www.ncbi.nlm.nih.gov/BLAST/) to find possibly existing additional mRNA 
or expressed sequence tag (EST) of a potential homolog of the already known 
gene.  
Accession numbers of the sequences used:  
HUMAN: MICL NM_138337 / AY547296, CLEC2 NM_016509 / AY358599, 
CLEC12B UNQ5782 / AK128243, CLEC9A NM_207345 / AY358265, CLEC1 
NM_016511 / BC067746, DECTIN-1 NM_022570 / AF313469, LOX-1 
NM_002543 / AB010710, FLJ31166 NM_153022 / AY358845, GABARAPL1 
NM_031412 / AF287012, CD94 NM_002262 / AY227806 
MOUSE: MICL NM_177686 / AK084335, CLEC12b AK016908, CLEC2 
NM_019985 / BC064054, CLEC9a NM_172732 / AK036399, CLEC1 
NM_175526 / AK031121, DECTIN-1 NM_020008 / AF262985, LOX-1 
NM_138648 / AK154687, “mouse FLJ31166” XM_284236, GABARAPL1 
NM_020590 / AK168921, NKG2i NM_153590 / AY100458, CD94 AK136548 
CHIMP:  MICL  XM_520734, CLEC2 XM_520735, CLEC12B XM_520736, 
(CLEC9A sequence – no accession number), CLEC1 XM_520737, DECTIN-1 
XM_528732, LOX-1  XM_528733, “FLJ31166” (incl. GABARAPL1 sequence) 
XM_520738, CD94 NM_001009062 
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DOG:  MICL XM_534891, CLEC12b XM_849067, CLEC2 XM_543823, 
CLEC9a XM_849058, CLEC1 XM_543822, DECTIN-1 XM_849050, LOX-
1 XM_543821,  “FLJ31166” M_849040, GABARAPL1 XM_848051 / 
XM_861857, CD94 XM_849017 
 
Sequence alignments and detection of homologies 
For alignments of shorter DNA and protein sequences the MacVector7.0 
software was used. For bigger alignments and alignments that should make 
genomic rearrangements detectable the Shuffle LAGAN tool (available at: 
http://lagan.stanford.edu/lagan_web/index.shtml) was used. 
Homologies of large genomic sequences were detected and plotted by the 
mVista Browser (available at: http://genome.lbl.gov/vista/index.shtml) using the 
AVID algorithm. For the detection of homologies between multiple short DNA 
and protein sequences the ClustalW algorithm of the MacVector7.0 software or 
the BLAST 2 SEQUENCES Version of the NCBI BLAST algorithm was used.  
For interspecies detection of conserved regions the ECR-Browser was used 
(available at: http://ecrbrowser.dcode.org/). 
 
Investigation of exon-intron structure, protein domains  
The exon-intron structure of the additional proteins was determined by aligning 
their mRNA sequences to the corresponding genomic region. When available 
the aligned sequences were obtained from the UCSC Genome Browser, 
otherwise alignments were produced using the MacVector7.0 software. All 
exon-intron boundaries were checked for the proper GT-AG boundary 
consensus sequence.  
To predict the protein domains of the additional proteins the EMBL SMART 
algorithm set to standard mode (available at: http://smart.embl-heidelberg.de/ 
(Schultz, Milpetz et al. 1998; Letunic, Copley et al. 2006)) was used. The 
predicted domains were then matched to the already determined exons of the 
gene.  
The SMART server provides the integrated output of several programs; the 
TMHMM2 (available at: http://www.cbs.dtu.dk/services/TMHMM/) program for 
prediction of transmembrane segments, the Coils2 program (available at: 
http://www.ch.embnet.org/software/COILS_form.html) for coiled coil regions, the 
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SignalP program (available at: http://www.cbs.dtu.dk/services/SignalP/) for 
Signal peptides and DisEMBL (available at: http://dis.embl.de/) for disordered 
regions (Linding, Jensen et al. 2003), (Bendtsen, Nielsen et al. 2004), (Nielsen, 
Engelbrecht et al. 1997). These programs were used for more detailed protein 
domain analysis.  
 
Construction of phylogenetic trees 
Because the C-terminal part of the lectin-like genes is highly variable and could 
bias the resulting phylogenetic tree only the CTLD sequences were used. The 
phylogenetic tree was constructed using default parameters of the ClustalW tool 
of the EBI (available at http://www.ebi.ac.uk/Tools/clustalw2/index.html) (Wilbur 
and Lipman 1983), (Myers and Miller 1988).  
 
Scanning of UTR sequences 
The investigation of the human CLEC9A UTR was performed using UTRScan, 
UTRdb and UTRblast (all available at: 
http://bighost.area.ba.cnr.it/BIG/UTRHome/).  
 
Structure Modeling 
Structure of not crystallized proteins was predicted based on the homology to a 
template sequence using SWISS MODEL WorkSPACE (available at: http:// 
swissmodel.expasy.org/workspace). Crystalized structure of dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN, 
1sl6A) was used as a template for the CLEC-1 structure model. 
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3) Results 
3.1) Expression of myeloid subfamily members in peripheral 
blood cells and endothelial cells  
 
To provide a comprehensive overview of the expression of CLEC-1, CLEC-2 
and DECTIN-1 in different subsets of human peripheral blood cells and 
endothelial cells, we investigated the corresponding mRNA expression and the 
surface localization of these receptors. 
 
3.1.1) Expression of CLEC-1, CLEC-2 and DECTIN-1 mRNA in 
peripheral blood cells 
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Figure 9: CLEC-1, CLEC-2 and DECTIN-1 mRNA expression in blood cell subsets. Real-Time RT-
PCR was performed using cDNAs obtained from peripheral blood cell subsets as templates. β-actin was 
used as internal control for normalization. Plasmids containing the corresponding cDNA were used as 
positive control (+ctrl), plasmids with unrelated cDNA served as negative control (-ctrl). Purity of cell 
fractions was controlled by FACS analysis using antibodies against appropriate cell marker molecules 
(see 3.1.2). A: 1% agarose gel showing the end products of a representative Real-Time RT-PCR 
experiment. B: Relative expression levels of CLEC-1, CLEC-2 and DECTIN-1 mRNA in blood cell 
subsets of one representative individual. Measurements were done in triplicates. The relative strength of 
expression was determined by normalizing the CLEC-1, CLEC-2 and DECTIN-1 mRNA levels to the 
corresponding β-actin mRNA levels.  
DECTIN-1 mRNA 
CLEC-1 mRNA 
CLEC-2 mRNA 
β-actin mRNA 
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To examine CLEC-1, CLEC-2 and DECTIN-1 mRNA levels, granulocytes, 
platelets, CD14+ monocytes, CD19+ B-lymphocytes and CD3+ T-lymphocytes 
were isolated from PBMC of healthy volunteers by MACS and processed for 
RNA isolation and cDNA synthesis. cDNA was then used for Real-Time RT-
PCR and the reaction end products were loaded on an agarose gel. 
Normalization of Real-Time RT-PCR data was carried out against β-actin as 
reference transcript, assuming that β-actin mRNA is present in similar amounts 
in the different cell types including platelets (Akbiyik, Ray et al. 2004). 
The data displayed the presence of mRNA for all three receptors in the whole 
PBMC population, in CD14+ monocytic cells as well as in granulocytes (figure 
9A). CLEC-2 mRNA was further present in platelets, whereas no transcripts for 
any of the receptors were detected in the CD3+ and CD19+ lymphocytic 
fractions.  
As shown in figure 9B, CLEC-2 mRNA levels as determined by quantitative 
Real-Time RT-PCR normalized to β-actin are significantly higher in 
granulocytes than in monocytes, and in platelets CLEC-2 mRNA even showed 
an about 1.000-fold higher level than in granulocytes.  
For DECTIN-1 mRNA levels were highest in monocytes, whereas CLEC-1 
mRNA levels seem to be similar for monocytes and granulocytes. As expected, 
due to the fact that PBMC consist of different cell populations, mRNA levels for 
all three receptors are lower in the total PBMC population as compared to some 
of the the isolated cell types. Significant expression in lymphocytic populations 
could not be detected (figure 9B). 
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3.1.2) Surface expression of CLEC-1, CLEC-2 and DECTIN-1 in 
peripheral blood cells  
 
To investigate whether all cell types expressing mRNA for CLEC-1, CLEC-2 
and DECTIN-1 would produce the protein and display the receptors on the cell 
surface, cells were stained with the respective antibodies and analysed by flow 
cytometry. The purity of the individual cell populations was confirmed using 
antibodies against the surface marker CD151 (platelets), CD15 (granulocytes), 
CD14 (monocytes) or CD3 (lymphocytes). As C-type lectin-like receptors of the 
NK gene complex are type II transmembrane proteins and are usually 
transported to the cell surface, non-permeabilized cells were stained. As in the 
case for the mRNA, surface staining for CLEC-1 and CLEC-2 was studied in 
comparison to DECTIN-1, for which coherent data were already available 
(Kanazawa 2007). 
As shown in figure 10, CLEC-2 could be detected on the surface of platelets 
and monocytes, but not on granulocytes, whereas DECTIN-1 was strongly 
expressed on monocytes and at lower levels on granulocytes. CLEC-1 was not 
detectable on the cell surface of any of the cell fractions tested. None of the 
receptors could be shown in the lymphocytic fraction. 
In regard of DECTIN-1 this data are consistent with the detected mRNA 
expression in monocytes and granulocytes. However, CLEC-1 could not be 
detected on the cell surface of any of the cell types, despite CLEC-1 mRNA was 
clearly identified at low but significant levels in monocytes as well as in 
granulocytes. Further, CLEC-2 transcripts can be found in platelets, monocytes 
and granulocytes, whereas flow cytometry detected CLEC-2 surface localization 
only for platelets and monocytes, but not for granulocytes. Compared to the 
high level of CLEC-2 mRNA in platelets, the surface staining of platelets 
appears to be only moderate (figure 10). 
Therefore, it seems that despite the presence of CLEC-1 and CLEC-2 mRNA in 
certain cell types the corresponding receptor is not expressed on the cell 
surface.  
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Figure 10: Surface expression of CLEC-1, CLEC-2 and DECTIN-1 in blood cell subsets. 
Surface expression of endogenous CLEC-1, CLEC-2 and DECTIN-1 in platelets, granulocytes, 
monocytes and lymphocytes was tested by flow cytometry after staining with the appropriate 
primary (mouse anti-human CLEC-1, CLEC-2 or DECTIN-1) antibody and a secondary FITC-
labeled anti-mouse antibody. Platelets and granulocytes were isolated from whole peripheral 
blood, monocytes and lymphocytes are populations gated from stained total PBMC samples as 
depicted in figure 13. Unfilled, black peak corresponds to isotype control staining. Stainings of 
cells of one individual representative for high CLEC-2 expressing donors are shown. 
 
In addition to the primary cell types isolated from blood, the lymphocytic cell 
lines Jurkat (acute T-lymphocyte leukemia cell line), 721.221 (EBV transformed 
B-lymphoblastoid cell line), NK-92 (NK lymphoma cell line) and the myeloid cell 
lines Mono-Mac-6 (acute monocytic leukemia cell line) and K-562 (human 
chronic myeloid leukemia cell line) were tested for surface expression of CLEC-
1, CLEC-2 and DECTIN-1. None of the cell types tested showed expression of 
CLEC-2 or CLEC-1, only K-562 stained positive for DECTIN-1 surface 
expression (figure 11). 
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Figure 11:  Surface expression of CLEC-1, CLEC-2 and DECTIN-
1 on leukemia cell lines. Expression of endogenous CLEC-1, 
CLEC-2 and DECTIN-1 was investigated by flow cytometry after 
staining with the appropriate primary (mouse anti-human CLEC-
1/CLEC-2/DECTIN-1) antibody and a secondary FITC-labeled anti-
mouse antibody. Unfilled, black peak corresponds to isotype control 
staining. One exemplary experiment out of three performed is shown. 
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3.1.3) Expression of the receptors in endothelial cells  
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Figure 12: Expression of endogenous and recombinant CLEC-1, CLEC-2 and DECTIN-1 receptors 
in HUVEC. The presence of endogenous CLEC-1, CLEC-2 and DECTIN-1 mRNA was tested by RT-
PCR and a potential surface expression for CLEC-1 evaluated by flow cytometry. The intracellular 
localization of the receptors following recombinant expression of CLEC-1, CLEC-2 and DECTIN-1 in 
HUVEC was investigated by immunofluorescence staining and flow cytometry. One representative 
experiment is shown. A: 1% agarose gel showing PCR products corresponding to CLEC-1, CLEC-2 and 
DECTIN-1 mRNA in cDNA preparations from HUVEC. Plasmids containing the appropriate or unrelated 
cDNA were used as positive or negative control, respectively.  B: FACS analysis of non-permeabilized 
HUVEC stained with mouse anti-human CLEC-1, CLEC-2 or DECTIN-1 antibodies and secondary anti-
mouse FITC labeled antibodies. (red peak: mouse anti-human CLEC-1, CLEC-2 or DECTIN-1 
antibodies, black peak: antibody isotype control) C: Immunofluorescence staining of permeabilized 
HUVEC infected with the recombinant adenoviruses AdVCLEC-1, AdVCLEC-2 or AdVDECTIN-1. Cells 
were stained with the corresponding mouse anti-human CLEC-1, CLEC-2 or DECTIN-1 antibodies and 
secondary anti-mouse FITC labeled antibodies. Magnification used: 1000x. D: FACS analysis of non-
permeabilized, adenovirus-infected HUVEC. HUVEC infected with AdVCLEC-2 were stained with mouse 
anti-human CLEC-2 and secondary anti-mouse FITC labeled antibody. HUVEC infected with AdVCLEC-
1 or AdVDECTIN-1 were stained with anti-FLAG FITC labeled antibody (red peak: AdVCLEC-1, 
DECTIN-1, black peak: AdVCtrl). 
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Human umbilical vein endothelial cells (HUVEC) had been shown previously to 
contain detectable amounts of CLEC-1 mRNA (Sobanov, Bernreiter et al. 
2001), but not CLEC-2 and DECTIN-1 mRNA. Consistently, mRNA for CLEC-1 
could be detected in HUVEC (figure 12A). However, when HUVEC were tested 
for surface expression of CLEC-1, no staining on the cell surface was 
detectable (figure 12B).  
As the expression levels of endogenous CLEC-1 and CLEC-2 in HUVEC and 
monocytes are quite low, the detection of the endogenous receptors with the 
available antibodies by flow cytometry and immunofluorescence staining 
frequently proved difficult. Therefore recombinant adenoviruses for the 
expression of the receptors were generated to facilitate studies of intracellular 
localization and of ligand binding properties. Following infection with the 
respective recombinant adenoviruses, cells were either permeabilized and 
processed for immunofluorescence to test for detectable protein inside the cells, 
or not permeabilized and analysed by flow cytometry to investigate surface 
localisation of the receptors. Whereas DECTIN-1 and CLEC-2 showed clear 
surface expression in immunofluorescence as well as in flow cytometry, 
recombinant CLEC-1 was not exposed at detectable levels at the cellular 
surface although there was strong intracellular expression ((figure 12C, 12D). It 
seems therefore that not only endogenous CLEC-1, but also overexpressed 
recombinant CLEC-1 in HUVEC is not transported to the cell surface and 
CLEC-1 may have a normal intracellular localization (see below in chapter 3.3) 
Intracellular localization of CLEC-1).  
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3.2) Expression of CLEC-2 on monocytes 
 
While this work was in progress, CLEC-2 expressed on the surface of platelets 
has been demonstrated to be the physiological ligand of podoplanin, a highly 
glycosylated cell surface protein (Suzuki-Inoue, Kato et al. 2007). As we found, 
in addition to expression on platelets, significant CLEC-2 receptor expression 
also on primary blood CD14+ monocytic cells, we investigated the potential 
significance of CLEC-2 for monocytes. This appeared to be of interest, as 
CLEC-2 might mediate binding of monocytes to cell types with high podoplanin 
expression such as lymphatic endothelial cells or tumor cells. 
 
3.2.1) CD14+ monocytes express CLEC-2 in varying amounts 
 
To investigate CLEC-2 expression on monocytes in more detail, whole PBMC 
isolated from peripheral blood of healthy adult volunteers and CBMC from cord 
blood (kindly provided by Anita Jandrositz/Karl-Heinz Preisegger, EccoCell 
Biotechnology, Austria) were tested for CLEC-2 staining in comparison to 
CLEC-1 and DECTIN-1 staining by flow cytometry. Both CLEC-2 and DECTIN-1 
could be shown to be expressed on the gated monocytic subpopulation of 
PBMC as well as of CBMC. Positive CLEC-1 staining could never be detected 
despite the presence of the corresponding mRNA (see figure 12A).  
DECTIN-1 staining defined a homogeneous DECTIN-1 positive cell population, 
which corresponds clearly to the CD14+ monocytic subpoplation in PBMC and 
CBMC. Further, DECTIN-1 seems to be equally strong expressed in PBMC and 
CBMC (figure 13) and always showed similar strength of expression in samples 
from different donors (data not shown). 
CLEC-2 antibodies on the other hand only stained a subpopulation of monocytic 
cells, suggesting that there might be two subpopulations of monocytes, one 
expressing CLEC-2 and the other lacking CLEC-2 expression (figure 13).  
It is intriguing, that CLEC-2 staining of monocytes seemed to be generally 
weaker on CBMC samples and showed clear variation in the level of expression 
when different donors are compared (figure 13, 14). 
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Figure 13: Evaluation of the expression of CLEC-1, CLEC-2 and DECTIN-1 receptors on the 
monocytic subpopulation of PBMC and CBMC. PBMC were isolated from peripheral blood, CBMC from 
cord blood and stained using primary mouse anti-human CLEC-1, CLEC-2 or DECTIN-1 antibodies and a 
secondary FITC-labeled anti-mouse antibody. FITC-labeled cells in the total PBMC or CBMC population 
are shown. The lymphocytic subpopulation is displayed in green (gate R1 in forward versus side scatter 
dot plot), the monocytic subpopulation in red (gate R2 in forward versus side scatter dot plot). Quadrants 
are drawn to delineate the staining of the isotype control antibody. Histograms show the expression of 
CLEC-1, CLEC-2 and DECTIN-1 on the gated monocytic subpopulation. Red peak: anti- CLEC-1, CLEC-2 
or DECTIN-1  staining, black peak: isotype control staining. One PBMC sample representative for donors 
with strong CLEC-2 expression (out of 10 samples) and one representative CBMC sample (out of 6 
samples) is shown. A: PBMC B: CBMC  
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Figure 14: Variation of CLEC-2 expression on the monocytic subpopulation of 
PBMC. PBMC were isolated from peripheral blood and stained with a primary 
mouse anti-human CLEC-2 antibody and a secondary FITC-labeled anti-mouse 
antibody. Expression of CLEC-2 on the monocytic subpopulation of two different 
PBMC samples, one representative for strong (10 samples) and one representative 
for weak (6 samples) CLEC-2 expressing donors. Histograms show the gated 
monocytic fractions corresponding to the populations boxed in red squares in the 
dot plots. Red peak: anti-CLEC-2 staining, black peak: isotype control staining. Dot 
plots show FITC-labeled cells in total PBMC, the monocytic subpopulation 
displayed in in red boxes. The horizontal lines are drawn to delineate the area of 
cells incubated with the isotype control antibody. 
 
In total PBMC from 18 and CBMC from 11 donors were isolated and 
investigated for CLEC-2 expression on monocytes. In PBMC more than half of 
the donors showed high (>20% CLEC-2 positive cells) and about one third low 
(<20% CLEC-2 positive cells) expression of CLEC-2, about 10% of all samples 
tested were negative (table 1). For CBMC, none of the donors expressed 
CLEC-2 strongly and only about 50% of all samples were weakly positive for 
CLEC-2 expression. 
 
PBMC CBMC 
> 20% CLEC-2+ < 20% CLEC-2+ negative > 20% CLEC-2+ < 20% CLEC-2+ negative 
10 (56%) 6 (34%)  2 (11%) 0 (0%) 6 (55%) 5 (45%) 
Table1: Statistics of CLEC-2 expression on PBMC and CBMC. All PBMC and CBMC samples tested were 
counted and classified according to the level of CLEC-2 expression in three groups. High: >20% CLEC-2+, low: 
<20% CLEC-2+ and negative samples.  
 
-57- 
We found varying CLEC-2 levels not only when samplesobtained from different 
donors where tested, but also when we collected blood from one single donor at 
different times. PBMC of one donor were investigated for expression of CLEC-2 
and DECTIN-1 at four different times (about 2 months apart) showing that 
CLEC-2 expression levels varied significantly. The highest expression levels 
were found the second time and third time we tested this donor (figure 15). The 
strength of DECTIN-1 expression on the other hand was equally strong at every 
time point tested. 
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Figure 15: Expression of CLEC-2 and DECTIN-1 on monocytes of samples obtained at 
different time points from one donor. PBMC were isolated from peripheral blood and stained with 
primary antibodies against CLEC-2 and DECTIN-1 (mouse anti-human CLEC-2 or DECTIN-1) and a 
secondary FITC-labeled anti-mouse antibody. CLEC-2 and DECTIN-1 staining on the gated 
monocytic fraction (gating see figure 13) of PBMC obtained at four different times are shown. Red 
peaks correspond to anti-CLEC-2 or anti-DECTIN-1 staining, black peaks correspond to staining 
with iisotype control. 
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3.2.2) CLEC-2 protein expression in peripheral blood cell subsets 
 
A B 
 
  
Figure 16: CLEC-2 protein expression can be detected in monocytes and platelets. Blood 
cell subsets were isolated and fractionated into membrane, cytoplasmic and nucleic fractions. 
Fractions were processed for Western Blotting. CLEC-2 protein was detected using a primary 
mouse anti-human CLEC-2 and a secondary HRP-labeled anti-mouse antibody. A: cytoplasmic, 
membrane and nucleic fraction of AdVCLEC-2 infected HUVEC used as positive control. B: 
membrane fractions of blood cell subtypes. 
 
To further confirm data about CLEC-2 expression on subsets of peripheral 
blood cells obtained by flow cytometry, we performed Western Blot analysis. 
Taking into account previous findings by FACS and RT-PCR, we could expect 
only low protein levels in monocytic cells. Therefore we isolated the membrane 
fractions of the various cell types to obtain samples enriched for CLEC-2 
expression. Western blot analysis of endothelial cells overexpressing CLEC-2 
following infection with recombiant adenoviruses confirmed that CLEC-2 can be 
detected exclusively in the membrane fraction (figure 16A). 
In accordance with the FACS data, the Western blot clearly displays the 
presence of CLEC-2 in the membrane fraction of CD14+ monocytes (figure 
16B). As expected, high amounts of CLEC-2 protein was also detected in 
membranes of platelets (Suzuki-Inoue, Fuller et al. 2006), whereas endothelial 
cells as well as CD3+ and CD19+ lymphocytic cells did not show detectable 
CLEC-2 protein expression, which is in line with the absence of corresponding 
mRNAs in these cell types. However, membrane fractions of granulocytes did 
not contain detectable amounts of CLEC-2 protein, despite CLEC-2 mRNA was 
clearly detectable in granulocytes (see figure 9A), suggesting a translational 
control level for CLEC-2 protein production.  
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3.2.3) Evaluation of a potential role of monocytic CLEC-2 in cell-cell 
adhesion 
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Figure 17: Adhesion of blood cell subpopulations to podoplanin expressing cells. Blood cell 
subtypes were isolated from peripheral blood, DiO-labeled and incubated with a monolayer of 
podoplanin expressing cells on a shaker. MCF-7 stably transfected with podoplanin or lymphatic 
endothelial cells expressing podoplanin in combination with AdVCLEC-2-infected K-562 were 
used as positive control, MCF-7 or HUVEC without podoplanin expression in combination with 
AdVCtrl-infected K-562 were used as negative controls. The percentages of labeled cells retained 
on the cellular monolayers were calculated from flow cytometry data obtained after washing and 
trypsinization of the cells. Graphs correspond to one of two experiments perfomed in triplicates. 
Incubation was done with various DiO-labeled blood cell subpopulations as indicated. A: 
monolayer cells are MCF-7 with or without podoplanin. B: monolayer cells are immortalized 
lymphatic endothelial cells (LEC-tert) or HUVEC.  
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 Figure 18: Expression of podoplanin and CLEC-2. 
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Flow cytometry analysis using mouse anti-human 
podoplanin, mouse anti-human CLEC-2 and the 
respective isotype control antibodies. Red peaks show 
staining with mouse anti-human podoplanin or mouse 
anti-human CLEC-2. Black peak show staining with 
isotype control antibody. A: Expression of podoplanin on 
cells used in the monolayer as adherent cells in adhesion 
assays to show binding of CLEC-2 expressing cells to 
podoplanin expressing cells. B: Expression of CLEC-2 on 
K-562 infected with AdVCLEC-2 or AdVCtrl used as 
control suspension cells in adhesion assays. 
 
Podoplanin has been reported to be the physiological ligand of CLEC-2 (Kato, 
Kaneko et al. 2008), therefore it was of interest to investigate, whether CLEC-2 
expression on monocytes would mediate monocyte binding to podoplanin 
expressing cells. Adhesion assays were performed by incubating labeled 
suspension cells with CLEC-2 expression with adherent monolayer cells 
expressing podoplanin (figure 18) for 30min on a shaking platform. Afterwards 
cells in suspension were washed away and the bound suspension cells were 
harvested together with the monolayer cells by trypsinization and counted by 
flow cytometry.  
K-562 infected with AdVCLEC-2 used as positive control adhered strongly to 
podoplanin-transfected MCF-7 cells as well as to lymphatic endothelial cells 
expressing podoplanin, but did not adhere to control MCF-7 and HUVEC. As 
expected platelets also adhered strongly to both podoplanin+ MCF-7 and LEC, 
but not to the podoplanin- cells.  
Unfortunately, despite expression of moderate levels of CLEC-2 on monocytes 
there was no significant adherence of monocytes to podoplanin expressing cells 
as compared to podoplanin negative cells (figure 17) suggesting that the CLEC-
2 expression levels on monocytes do not suffice to reveal binding in the 
employed assay. 
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Further, we could not detect any specific cell adhesion by granulocytes and 
lymphocytes, which is in line with the findings that lymphocytes and 
granulocytes do not express CLEC-2 on their surface (figure 17).  
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3.3) Intracellular localization of CLEC-1  
 
CLEC-1 is the least investigated receptor of the myeloid subfamily of the human 
NK gene complex and only little information is available about this protein. It 
has been reported by our group that CLEC-1 mRNA is found in endothelial and 
dendritic cells, but information about its ligands and functions are not available 
so far, although the gene encoding CLEC-1 has been identified some years ago 
(Sobanov et al., 2001, Colonna, Samaridis et al. 2000). Considering the 
importance of the other family members in the natural immune system, it is 
likely that CLEC-1 has a similar important function. 
 
3.3.1) CLEC-1 shows all characteristics of C-type lectin-like receptors 
 
CLEC-1 is encoded in the NK gene complex together with several other C-type 
lectin-like receptors. It is flanked by its closest homologs CLEC-2 (telomeric) 
and DECTIN-1 (centromeric). Despite high homology is observed between 
CLEC-1 and these genes (Sobanov, Bernreiter et al. 2001), it does not seem to 
share the important attribute of surface expression with its other family 
members (see firgure 21). To investigate whether this striking difference could 
be explained by variations of the DNA and protein sequence, an analysis of the 
CLEC-1 sequence by bioinformatical approaches was conducted.   
By comparing the genomic region encoding human CLEC-1 with sequences 
available from chimpanzee, rhesus monkey, cow, mouse, rat and dog, we found 
the human and the two primate species tested (chimpanzee, rhesus monkey) to 
be almost identical. This high homology spreads over the whole genomic 
CLEC-1 sequence including exons as well as intronic areas. Further, there are 
still regions with the notable homology of about 50 to 70% when the human 
sequence is compared to the sequences of the non-primate species (cow, 
mouse, rat, dog). However, in non-primate species, significant homology is 
basically limited to protein coding exon regions. There are also some short but 
highly conserved areas in non-coding regions, which might show the existence 
of important regulatory elements (figure 19A).   
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An alignment of the human CLEC-1 and CLEC-2 protein sequences shows a 
high degree of sequence identity for 73 out of 280 amino acids (26%) and in 
addition 21% similar amino acids (figure 19A). The transmembrane regions 
display even 48% identity.  
 
A 
 
 
 
B 
 
Figure 19: CLEC-1 DNA and protein sequence analysis. A: Genomic sequence alignment showing 
the degree of similarity of the CLEC-1 genes of chimpanzee (panTro2), rhesus monkey (rheMac2), cow 
(bosTau3), mouse (mm9), rat (rn4) and dog (canFam2) with the human CLEC-1 gene (hg18). The 
height of the peaks indicate per cent similarity. Colours define different genomic regions. yellow: UTR, 
blue: coding exons, salmon: intronic regions, green: transposons and simple repeats. Alignment 
obtained by using the ECR Browser available at http://ecrbrowser.dcode.org  
B: Alignment of the human CLEC-1 and CLEC-2 protein sequences using the ClustalW2 algorithm set 
to default parameters (available at http://www.ebi.ac.uk/Tools/clustalw2/index.html?). asterisk: identity, 
colon: conserved substitutions, period: semi-conserved substitutions, TM: transmembrane region 
boxed in blue, conserved cysteins boxed in red.  
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A  CLEC-1 domain overview B  Coiled Coil region 
 
 
C  Transmembrane region D  Signal Anchor 
  
E  CLEC-1 and CLEC-2 Protein tertiary structure  
 
 
template:  DC-SIGN 1sl6A (2.25 Å) 
sequence identity: 19,774% 
E-value: 1.50e-26 
 
 
 
template: CLEC-2 2c6uA (1.60 Å) 
sequence Identity: 100% 
E-value: 3.11e-70 
Figure 20: Bioinformatic analysis of CLEC-1 protein sequence. A: Protein domain overview 
obtained using SMART (available at http://smart.embl-heidelberg.de/smart), horizontal blue box: region 
of intrinsic disorder, vertical blue box: transmembrane region, horizontal green box: coiled coil domain, 
pink CLECT box: C-type lectin region. B: Prediction of coiled coil regions using COILS Server 
(available at http://www.ch.embnet.org/software/COILS_form.html). C: Prediction of transmembrane 
region using TMHMM Server v. 2.0 (available at http://www.cbs.dtu.dk/services/TMHMM/). D: 
Prediction of signal peptides/anchors using SignalP 3.0 Server (available at 
http://www.cbs.dtu.dk/services/SignalP/) h-region: hydrophobic core region, n-region: positively 
charged NH2-terminal segment, c-region: COOH-terminal cleavage region. E: B: Structure model of 
CLEC-1 compared to CLEC-2 obtained using Swiss-Model Algorithm (available at 
http://swissmodel.expasy.org/workspace/index.php). DC-SIGN (1sl6A) was used as template sequence 
for CLEC-1. Template for the CLEC-2 model was the crystallized structure of CLEC-2 (2c6uA ) itself. 
 
CLEC-1 CLEC-2 
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Further investigation of the CLEC-1 protein sequence using bioinfomatics tools 
revealed a domain structure typical for all C-type lectin-like proteins. Like the 
other C-type lectins, CLEC-1 is predicted to contain a transmembrane region 
and C-type lectin-like domains, and in addition three regions of intrinsic disorder 
and a coiled coil domain could be identified (figure 20A). 
To characterize the predicted domains in more detail we used the programs 
generating the SMART predictions. Emphasis was given to the transmembrane 
region, which was predicted by the TMHMM Server calculating the total 
probability of a residue being located within a transmembrane helix, inside or 
outside of the membrane. In the CLEC-1 protein sequence the predicted 
transmembrane region spans 22 amino acids from residue 50 to residue 72, 
leaving 49 amino acids on the N-terminus as short cytoplasmic part of the 
protein and 208 amino acids at the outer side of the membrane harbouring the 
C-type lectin-like domains (figure 20C). Close to the membrane domain one of 
the programs also used by SMART (COILS) predicted a coiled coil region of 27 
amino acids length, which nicely correlates with exon three encoding the stalk 
of the protein (figure 20B).  As expected for a type II transmembrane protein the 
prediction program used (SignalP) did exclude the existence of an N-terminal 
signal peptide, but it could identify a signal anchor with a probability of 100% 
(figure 20D) corresponding nicely to the predicted transmembrane region. 
Therefore the bioinformatics analysis strongly supports a type II transmembrane 
localization for CLEC-1 similar to the other members of the family. Finally 
SMART also detected regions of intrinsic disorder on the N-terminal as well as 
on the C-terminal end of the protein.  Finally, a model of the CLEC-1 tertiary 
structure was produced using the Swiss Model Workspace. The program 
automatically chose the already crystallized DC-SIGN (Guo, Feinberg et al. 
2004) as the most suitable template and generated a model based on the 
homology to DC-SIGN. For comparison we also modeled the CLEC-2 structure. 
In this case the crystallized CLEC-2 itself was used as template. As depivted in 
figure 20E, a striking similarity between the CLEC-1 and the CLEC-2 structures 
is apparent. Like CLEC-2, CLEC-1 is predicted to consist of three α-helices, 
one of which is very short, associated with several β-sheets, causing a very 
similar general conformation. 
-66- 
3.3.2) The intracellular localization of CLEC-1 is not changed by cell 
activation 
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Figure 21: Expression of CLEC-1 after stimulation of endothelial cells. HUVEC were 
infected with AdVCLEC-1, stimulated for 5h with 10ng/ml TNF-α, 100ng/ml LPS or 1 µg/ml 
PMA and processed for Real-Time RT-PCR, flow cytometry and immunofluorescence 
staining using a primary mouse anti-human CLEC-1 and a secondary FITC-labeled anti-
mouse antibody, respectively. A: Relative levels of E-Selectin mRNA in HUVEC analysed by 
Real-Time RT-PCR to confirm the activation of HUVEC used for immunofluorescence and 
flow cytometry. Measurements were done in triplicates for each experiment. B: Flow 
cytometry analysis of endogenous CLEC-1 and recombinant CLEC-1 overexpressed by 
adenoviral infection on non permeabilized HUVEC. Red peaks show staining of stimulated 
cells. Black peak show staining of non-stimulated cells. Experiments were done twice in 
duplicates, one representative sample is shown. C: Immunofluorescence staining of 
recombinant CLEC-1 in permeabilized HUVEC. Experiments were done twice, one 
representative picture is shown. Magnification used: 1000x 
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As bioinformatics did not display any unusual feature in the CLEC-1 sequence 
and strongly supported a transmembrane localization similar to the other 
members of the family, the question arose why CLEC-1 could not be detected 
on the surface of cells with CLEC-1 mRNA. One possible explanation might be 
that CLEC-1 is retained intracellularly until the cell is challenged with a specific 
stimulus. As mRNA of CLEC-1 was found in endothelial cells, we used the 
inflammatory stimuli LPS and TNFα as well as PMA to stimulate HUVEC for 5h 
and tested for detectable surface expression of endogenous CLEC-1 by flow 
cytometry. To exclude that a failure to detect CLEC-1 would be caused by the 
low expression level of the endogenous CLEC-1 we also used recombinant 
overexpressio of CLEC-1 with a corresponding adenoviral construct. Although 
all three stimuli used strongly activated endothelial cells as shown by the 
upregulation of E-Selectin (figure 21A), we could not detect any surface 
expression of endogenous or overexpressed CLEC-1 (figure 21B). 
Permabilized endothelial cells overexpressing CLEC-1 showed an intracellular 
pattern of CLEC-1 staining without any detectable changes after stimulation 
(figure 21C) supporting a normal intracellular localization not influenced by the 
activation state of the cell.  
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3.3.3) The intracellular staining of CLEC-1 shows ER-like pattern  
 
Calnexin / Endoplasmic reticulum Golgin-97 / Golgi apparatus 
  
CLEC-1 CLEC-2 
  
Figure 22: Intracellular localization of recombinant CLEC-1 in HUVEC. HUVEC infected with 
AdVCLEC-1 were permeabilized and stained for CLEC-1 using a primary mouse anti-human CLEC-1 
and a secondary FITC-labeled anti-mouse antibody. Calnexin, Golgin-97 and CLEC-2 staining with 
corresponding primary mouse anti-human Calnexin, Golgin-97, or CLEC-2 antibodies and a secondary 
FITC-labeled anti-mouse antibody were used to compare the staining pattern of CLEC-1 to proteins 
with different localization within the cell. Stainings were done three times, one representative picture is 
shown. Magnification used: 1000x 
 
Intracellular staining of recombinant CLEC-1 in endothelial cells always showed 
perinuclear accumulation and thin structures with a net-like appearance 
reaching out towards the borders of the cell. Considering the fact that CLEC-1 
does not seem to be present on the cellular surface as indicated by flow 
cytometry data as well as immunoflourescence staining, but still possesses all 
characteristics of a transmembrane protein, it is plausible to propose that the 
normal physiological localisation of CLEC-1 is at an intracellular membrane. To 
test this hypothesis we performed immunofluorescence staining of endothelial 
cells infected with AdVCLEC-1 and AdVCLEC-2 as a control for surface 
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staining. We further stained non-infected cells with antibodies against Calnexin, 
a specific marker for the endoplasmic reticulum, and Golgin-97, used as marker 
for the Golgi apparatus. Comparing the staining patterns of the differently 
stained cells it became apparent that CLEC-1 staining did not resemble surface 
staining or Golgi-97 staining (figure 22). The observed CLEC-1 patterns most 
closely resembled calnexin staining. Therefore it appears that CLEC-1 is indeed 
preferentially localized to the endoplasmic reticulum membranes. 
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3.3.4) Endogenous CLEC-1 is localized in the ER of endothelial cells 
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Figure 23: Endogenous CLEC-1 in subcellular fractions of 
HUVEC. Subcellular fractions of endothelial cells were isolated and 
tested in Western Blots using primary mouse or rabbit antibodies 
against human CLEC-1, COX-1, nucleoporin-1, LAMP-1 and Calnexin-
1. Proteins were detected using secondary HRP-labeled anti-mouse or 
anti-rabbit antibodies. Cells infected with AdVCLEC-1 were used as 
positive control (+ctrl) for CLEC-1 expression. A: Cytoplasmic, 
membrane and nucleic fractions of HUVEC tested for CLEC-1. B: 
Cytoplasmic, mitochondrial, lysosomal, microsomal and nucleic 
fractions of HUVEC tested for CLEC-1. As organelle marker proteins 
COX-1 (mitochondria), Nucleoporin (nuclei), LAMP-1 (lysosomes) and 
Calnexin (Endoplasmic reticulum) were used.  
 
To further confirm that CLEC-1 is localized in intracellular membranes we 
produced subcellular fractions of endothelial cells and tested them for the 
presence of endogenous CLEC-1 by Western Blotting. We could clearly detect 
a preferential presence of CLEC-1 in the membrane fraction, whereas as 
expected CLEC-1 was absent from the cytoplasmic and nuclear fractions (figure 
23A). The hypothesis that endogenous CLEC-1 might be localized to the ER 
membrane could be further supported by another cell fractionation experiment. 
Subcellular fractions of endothelial cells enriched in cytoplasmic, mitochondrial, 
lysosomal, microsomal and nucleic proteins were prepared by differential 
centrifugation. As differential centrifugation can not achieve totally pure 
fractions, it was important to stain for marker proteins in each fraction to define 
-71- 
the degree of purity. Marker proteins used were cytochrome c oxidase subunit 1 
(COX-1) for the mitochondrial fraction, nucleoporin for the nucleic fraction, 
lysosomal-associated membrane protein 1 (LAMP-1) for the lysosomal fraction 
and calnexin for the endoplasmic reticulum fraction. This experiment showed 
that CLEC-1 staining was clearly strongest in the ER fraction (figure 23B, 
although smaller amounts of CLEC-1 could also be detected in the 
mitochondrial and lysosomal fractions, which is probably due to contamination 
of these fractions with ER proteins. As expected, no staining of CLEC-1 in the 
cytoplasmic and the nuclear fraction could be observed.  
-72- 
3.3.5) CLEC-1 and intracellular TLR ligands 
 
The fact that CLEC-1 is found only intracellularly but is a member of a family of 
mainly surface located receptors is reminiscent of the situation in the TLR 
receptor family. Furthermore, similar to TLRs some of the C-type lectin-like 
receptors show characteristics of pattern recognition receptors. In the case of 
the intracellular TLR9 it has been described that upon binding to its ligand TLR9 
translocates between different intracellular compartments (Latz, Schoenemeyer 
et al. 2004). Since it was possible that CLEC-1 would have similar ligands as 
TLRs or would translocate between different compartments together with TLRs, 
possible effects of ligands for the intracellular TLR3, 7 and 9 on CLEC-1 mRNA 
expression level and intracellular localization were investigated. As endogenous 
CLEC-1 is expressed in dendritic cells, we differentiated cord blood derived DC, 
stimulated them with the TLR ligands poly(I:C), Imiquimod and CpG-ODN and 
analysed CLEC-1 expression by Real-Time RT-PCR and immunofluorescence 
staining.  
 
3.3.5.1) Marker expression on cord blood derived dendritic cells  
 
Dendritic cells were differentiated from CD34+ progenitor cells isolated from 
cord blood and tested for expression of CD11b and CD1a as markers for DC. 
Cells were confirmed to express both CD11b and CD1a, but not CD14, a 
monocytic marker (figure 24A, 24B). mRNA transcripts for DECTIN-1, CLEC-1 
and CLEC-2 were clearly detected by PCR (figure 24C). 
 
 
 
-73- 
 
A 
 
  
Is
o-
P
E
 
 
   
   
C
D
11
b-
P
E
 
CD1a-APC                Iso-APC 
B      
CD1a-APC 
 
CD11b-PE 
 
CD14-FITC 
C
el
l c
ou
nt
 
 
C
el
l c
ou
nt
 
 
C
el
l c
ou
nt
 
 
relative fluorescence 
intensitiy 
relative fluorescence  
intensitiy 
relative fluorescence  
intensitiy 
C 
 
Figure 24: Analysis of surface 
markers and DECTIN-1, CLEC-1 
and CLEC-2 mRNA expression in 
CBDC. CBDC were differentiated 
from CD34+ cord blood progenitor 
cells and tested for the expression 
of the dendritic cell markers CD11b 
and CD1a and the monocytic 
marker CD14 by flow cytometry 
using mouse anti-human CD11b-
PE, CD1a-APC and CD14-FITC 
antibodies and the corresponding 
isotype controls. Analysis of marker 
expression was done after each 
differentiation, one representative 
sample is shown. PCR was used to 
detect CLEC-1, CLEC-2 and 
DECTIN-1 transcripts in CBDC 
cDNA. A: Dot plot confirming 
double staining of both CD11b and 
CD1a on CBDC. B: Histograms 
showing expression of CD11b, 
CD1a and CD14. Red peaks show 
staining with mouse anti-human 
CD11b-PE, CD1a-APC or CD14-
FITC. Black peaks show staining with 
the corresponding isotype control 
antibody. C: 1% agarose gel 
showing PCR products 
corresponding to CLEC-1, CLEC-2 
and DECTIN-1 mRNA in CBDC 
cDNA preparations. Plasmids 
containing the appropriate or 
unrelated cDNA were used as 
positive or negative control, resp. 
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3.3.5.2) CLEC-1 mRNA is downregulated upon activation of dendritic cells  
 
 
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
ls
 
of
 C
LE
C
-1
 
 
 
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
ls
 
of
 C
LE
C
-2
 
 
 
 
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
ls
 
of
 D
EC
TI
N
-1
 
 
 
Figure 25: Regulation of CLEC-1, CLEC-2 and DECTIN-1 in CBDC. 
Regulation of mRNA levels of CLEC-1, CLEC-2 and DECTIN-1  in CBDC upon 
simulation with 25µg/ml poly(I:C), 1µM CpG-ODN, 10µg/ml Imoquimod, 
100ng/ml LPS, 10ng/ml TNF-α and 1 µg/ml PMA. CBDC were stimulated for 2h 
and over night with various stimuli and processed for RNA isolation and cDNA 
synthesis. Real-Time RT-PCR was performed using β-actin as internal control 
for normalization. mRNA levels in stimulated cells relative to unstimulated cells 
are shown for CLEC-1, CLEC-2 and DECTIN-1. Measurements were done in 
triplicates. 
 
Considering the possibility that CLEC-1 might be an intracellular pattern 
recognition receptor, it was of interest to investigate whether TLR ligands or 
other inflammatory stimuli would show any regulatory effect on CLEC-1 
poly(I:C) CpG-ODN Imiquimod LPS TNFα PMA 
CLEC-1 
CLEC-2 
DECTIN-1 
poly(I:C) CpG-ODN Imiquimod LPS TNFα PMA 
poly(I:C) CpG-ODN Imiquimod LPS TNFα PMA 
-75- 
expression in dendritic and endothelial cells. To this end dendritic cells were 
differentiated from CD34+ positive progenitor cells from cord blood. The 
obtained cells were then stimulated with 25µg/ml poly(I:C), 1µM CpG-ODN 
(CpG oligo-desoxy-nucleotide), 10µg/ml Imiquimod (R484), 100ng/ml LPS, 
10ng/ml TNF-α and 1 µg/ml PMA for different time points and processed for 
RNA isolation, cDNA synthesis and Real-Time RT-PCR detection of CLEC-1 
transcript levels. CLEC-2 and DECTIN-1 mRNA levels were included for 
comparison. Poly(I:C), CpG-ODN and Imiquimod mimic bacterial and viral 
nucleic acids and are used as synthetic ligands for TLR-3 (binds viral dsRNA in 
the endosome), TLR-9 (binds unmethylated bacterial DNA) and TLR-7 (binds 
viral ssRNA) respectively. LPS, TNF-α and PMA were included as additional 
known stimuli of DC maturation. 
As shown in figure 25, the substances used generally seemed to cause 
downregulation of all three receptors in cord blood derived dendritic cells, 
presumably indicative of a stimulus for maturation of the cells following 
triggering of the respective receptors. When compared to DECTIN-1, CLEC-1 
downregulation was most pronounced upon treatment of CBDC with poly(I:C) 
and CpG-ODN, whereas imiquimod did not seem to affect CLEC-1 mRNA 
levels at all. A similar pattern of downregulation was observed for CLEC-2, 
whereas DECTIN-1 was affected most strongly by Imiquimod. CpG-ODN 
showed no significant effect on DECTIN-1 mRNA levels. Control non-CpG-ODN 
(GpC instead of CpG dinucleotides) did not have any effect on any of the 
receptors (data not shown). LPS, TNF-α and PMA caused downregulation of all 
three receptors, the effect being most pronounced for mRNA levels of DECTIN-
1. 
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3.3.6) CLEC-1 and intracellular pathogens 
 
It is generally accepted that receptors of the myeloid receptor family, for which 
the ligands are known, function as pattern recognition receptors (Kanazawa 
2007). As our data suggest that CLEC-1 is expressed intracellularly and may 
have an intracellular "pattern recognition" function, we investigated whether 
there might be any effect on CLEC-1 upon infection of the cells with intracellular 
pathogens indicative of a role of the receptor in the response towards these 
pathogens. As examples for common intracellular pathogens the eukaryotic 
parasite Toxoplasma gondii and the gram-positive bacteria Listeria 
monocytogenes were investigated. 
Inside the host cell T.gondii is surrounded by a cell membrane creating the 
parasitophorous vacuole in which the parasite is protected from being killed by 
cellular defence mechanisms. The infection process of Listeria monocytogenes 
on the other hand results in the bacteria being surrounded by a two-
membrane vacuole from which they need to escape into the cytosol where 
they replicate.  
It might be possible that the host cell senses Toxoplasma gondii or Listera 
monocytogenes infection via a receptor in these vacuole membranes, and given 
the already known characteristics of CLEC-1 it could be a possible candidate 
for this function. Therefore we tested different possibilities of interactions 
between CLEC-1 and the two chosen pathogens, Toxoplasma gondii and 
Listeria monocytogenes. 
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3.3.6.1) Toxoplasma gondii and Listeria monocytogenes 
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Figure 26: HUVEC infected with Listeria monocytogenes and Toxoplasma gondii. HUVEC 
were seeded and infected for two days with Listeria monocytogenes and Toxoplasma gondii at a 
MOI of 100 and 10, respectively. Pictures were taken under phase contrast and following staining 
with DAPI using UV light. Magnification used: Toxoplasma gondii: 500x, Listeria monocytogenes 
1000x. 
 
To investigate possible effects of Toxoplasma gondii and Listeria 
monocytogenes infection on CLEC-1, Toxoplasma gondii and Listeria 
monocytogenes were amplified and either used for infection of cells or purified 
and directly used for binding studies. Infection of cells was done at a MOI of 
100 for Listeria monocytogenes and a MOI of 10 for Toxoplasma gondii. 
Infected endothelial cells were analysed by microscopy, Toxoplasma gondii 
having a size of approximately 6x2 µm are visible in phase contrast at a 500-
fold magnification and can be stained with the DNA dye DAPI and detected in 
the UV channel. Listeria monocytogenes can only be detected by DAPI staining 
(figure 26).  
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3.3.6.2) CLEC-1 is not affected by T. gondii and L. monocytogenes 
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Figure 27: Localisation of CLEC-1 in HUVEC after infection with parasites. HUVEC overexpressing 
CLEC-1 were infected with Toxoplasma gondii and Listeria monocytogenes and tested for intracellular 
CLEC-1 relocalisation by immunofluorescence staining using a primary mouse anti-human CLEC-1 and a 
secondary FITC-labeled anti-mouse antibody. Cell nuclei were visualized using DAPI (blue). 
Magnification used: 1000x 
 
It was conceivable, that if CLEC-1 would interact with Toxoplasma gondii or 
Listeria monocytogenes within the cell, it would be possible to detect CLEC-1 in 
close proximity to the pathogens, as a membrane receptor potentially 
accumulating in the vacuole membrane. To test this hypothesis we performed 
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immunofluorescence staining of cells overexpressing CLEC-1 in comparison to 
cells overexpressing CLEC-2 and infected with Toxoplasma gondii or Listeria 
monocytogenes. CLEC-1 and CLEC-2 staining showed the usual pattern, the 
first being expressed intracellularly and the second on the cell surface, but no 
changes in localization of either CLEC-1 or CLEC-2 was apparent when the 
cells were infected with Toxoplasma gondii or Listeria monocytogenes (figure 
27). It could be shown that the lumen of the parasitophorous vacuole clearly 
lacks CLEC-1 expression and that there is no re-localisation to the vacuole 
membrane causing accumulation of CLEC-1. The same holds true for CLEC-2.  
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Figure 28: Binding of CLEC-1 to parasites. Toxoplasma gondii and Listeria monocytogenes 
were isolated and directly tested for binding to soluble CLEC-1 or used for infection of HUVEC. 
A: Isolated parasites were incubated with soluble CLEC-1, washed thoroughly, stained using a 
FITC-labeled anti-FLAG antibody and analysed by flow cytometry. The black peak shows 
background staining of parasites incubated without soluble CLEC-1 protein. B: Infected HUVEC 
were incubated with soluble CLEC-1, washed thoroughly, stained using a FITC-labeled anti-
FLAG antibody and analysed by flow cytometry. The black peak shows background staining of 
non-infected HUVEC. C: Infected HUVEC expressing recombinant CLEC-1 were tested for 
CLEC-1 surface expression, using a primary mouse anti-human CLEC-1 and a secondary 
FITC-labeled anti-mouse antibody. The black peak shows background staining of non-infected 
HUVEC. 
 
To test whether CLEC-1 is capable of binding directly to isolated Toxoplasma 
gondii or Listeria monocytogens, we amplified and isolated the pathogens and 
incubated them with soluble CLEC-1. We further tested, whether CLEC-1 would 
bind a ligand upregulated on the cell surface after infection of the cell with either 
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Toxoplasma gondii or Listeria monocytogenes, by infecting HUVEC with both 
pathogens and incubating the infected cells with soluble CLEC-1.  
However, we could not detect any specific binding of soluble CLEC-1, neither 
directly to the isolated parasites nor to the surface of infected cells (figure 28A, 
28B). The same is true for soluble DECTIN-1, which we used in addition as a 
control (data not shown). Soluble proteins containing the CLEC-1 or DECTIN-1 
ectodomaim, as well as a FLAG-tag, were kindly provided by Mag. Irene Karas. 
Although we never found surface expression of CLEC-1 on any cell type and 
propose that CLEC-1 might function intracellularly, it still can not be excluded 
completely that CLEC-1 is only expressed on the cell surface upon the 
appropriate stimulation of the cell. Therefore we further tested whether 
Toxoplasma gondii or Listeria monocytogenes infection would cause CLEC-1 to 
be transported to the surface. To this end HUVEC overexpressing CLEC-1 
were infected with Toxoplasma gondii and Listeria monocytogenes, stained for 
CLEC-1 surface expression and analysed by flow cytometry.  As shown in 
figure 28C CLEC-1 could not be shown to be localized on the cell surface after 
Toxoplasma gondii or Listeria monocytogenes infection. 
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3.4) Genomic analysis of the myeloid cluster of the murine and 
human NK gene complex 
 
The genes encoded in the myeloid receptor part of the human NK receptor 
complex have become the focus of intense investigations in recent years, in 
particular since several of them, such as LOX-1 and DECTIN-1, were shown to 
play a pivotal role in the initiation and regulation of immune responses. When 
this work was initiated, there were still large unknown genomic regions between 
these genes, which had not been analysed before for protein encoding regions, 
therefore we decided to study these regions to potentially identify additional 
lectin-like genes. 
To this end an extensive comparison of the sequences of the myeloid receptor 
part of the human, chimpanzee, mouse and rat NK complexes was conducted, 
based on sequences which have recently become available by whole genome 
sequencing.  
 
3.4.1) Identification of additional C-type lectin-like genes  
 
A 
 
 
 
 
 B 
              
Figure 29: Organization and transcriptional orientation of the genes of the human and mouse NK 
receptor complex between MICL and CD94. Physical map of the approx. 380 kb region extending from the 
MICL gene on the telomeric side to the CD94 gene on the centromeric side of the NK receptor complex. By 
searching for mRNA and EST sequences four additional genes were identified in the human as well as in the 
murine NK receptor complex. Linkage, orientation and distance between the genes in the centromeric part 
were delineated from sequence information available from the human genome project.  A: Linkage and 
orientation of the lectin-like genes in the centromeric part of the human NK receptor gene complex on the 
short arm of chromosome 12. B: Linkage and orientation of the lectin-like genes in the syntenic region of the 
murine NK receptor gene complex on chromosome 6. C: Homology blot showing the homology between the 
corresponding human and the murine sequences of the NK gene complex. The Blot was produced using 
mVista (VistaBrowser, http://genome.lbl.gov/vista/mvista/submit.shtml) with the human genome as base 
genome.  
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The human NK receptor complex spans a region of approximately 2 Mb on the 
short arm of the human chromosome 12 (12p12.3-p13.2) (Renedo, Arce et al. 
1997; Sobanov, Glienke et al. 1999) whereas the syntenic region in mice is 
located on chromosome 6 (6qF3) (Brown, Fulmek et al. 1997), in rats on 
chromosome 4 (4q42) (Dissen, Ryan et al. 1996) and in cow sequences of the 
genes encoded in the human complex can be aligned to chromosome 5.  
In order to identify additional genes, sequence databases for human and 
murine mRNA and EST sequences aligning to the NK receptor complex were 
searched. We focused on the myeloid receptor cluster of the NK complex 
extending from the MICL (CLEC12a) gene on the telomeric side to the CD94 
gene on the centromeric side. This region is known to encode lectin-like 
receptors predominantly expressed in cells of the myeloid lineages and spans 
about 343 kb in humans, whereas it is about 100 kb shorter in mice (248 kb). 
This difference in size can be explained on the one hand by two insertions into 
the human genome comprising 30 and 50 kb, respectively, and on the other 
hand by a higher percentage of repetitive elements in the human cluster 
(51,38%) compared to the murine cluster (32,88%), which is mainly due to a 
higher amount of Alu elements (human: 15,12%, mice: 2,12% of whole 
sequence). 
Sequence comparisons identified mRNA and EST sequences for four additional 
genes (figure 29A). Two of these, CLEC12b (corresponding to 
Refseq.UNQ5782) and CLEC9A (corresponding to Refseq.NM_207345), are 
encoded between CLEC-2 and CLEC-1 whereas the other two genes, 
FLJ31166 and GABA(A) receptor-associated protein like 1 (GABARAPL1), are 
located centromeric of LOX-1. Interestingly, CLEC-2 and CLEC12b occur in 
exchanged order and transcriptional orientation in mice when compared to men 
whereas the other genes show identical order and orientation (figure 29A). 
Human GABARAPL1 shares 87% amino acid sequence identity with GABA(A) 
receptor-associated protein (GABARAP) and is known to be expressed at high 
levels in the central nervous system (Nemos, Mansuy et al. 2003) and in 
various other organs (Xin, Yu et al. 2001), but has not yet been described in the 
context of the human NK gene complex. GABARAPL1 is a member of a group 
of three human paralogues and two mouse orthologues of human GABARAP, 
which is encoded on human chromosome 17, and belongs to a microtubule-
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associated protein family. It was the first protein identified to interact with the γ2 
subunit of GABA(A) receptor (Xin, Yu et al. 2001)(Wang, Bedford et al. 1999).  
One gene which could be identified in the murine but not in the human complex 
is located telomeric of CD94, described as murine NKG2i, also called KLRE1. 
KLRE1 was shown recently to function as a heterodimer with the ITIM-bearing 
KLRI1 or KLRI2, thereby generating an inhibitory receptor complex on NK cells 
and a subpopulation of CD3+ cells (Westgaard, Dissen et al. 2003; Saether, 
Westgaard et al. 2008). It was not possible to find a human homolog to murine 
NKG2i in the corresponding region of the human NK gene complex. 
As depicted in figure 29B, a clear homology is visible between the genomic 
regions of the human and murine myeloid clusters, which displays the 
difference in conservation between coding and non-coding regions. In the 
region encoding CLEC-2 and CLEC12b no detectable homology between the 
human and mouse sequences is detected in the analysis, which is explained by 
the finding that this region is inverted in the murine compared to the human 
genome as will be discussed below.  
Homology analysis further detects areas of low homology in the alignment of 
the genomic sequence of the human and murine region between GABARAPL1 
and CD94. Although this region in mice contains the NKG2i gene, the areas in 
this region displaying some homology do not correspond to the murine NKG2i 
exons. In the human genome the low homology areas are actually within an 
insertion of about 60 kb present only in the human cluster. 
In addition, centromeric of GABARAPL1 a short stretch of approximately 140 bp 
seems to be highly conserved between human and mouse. By searching for 
regulatory elements a putative binding site for the OCT1 transcription factor 
could be detected there, assuming that this region might play a role in 
regulation of one of the surrounding genes (figure 29B). 
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3.4.2) Gene arrangement in primate and non-primate species 
 
 
Figure 30: Conformation of the NK 
gene complex between MICL and 
CLEC1. Possible events leading from the 
non-primate to the primate gene 
arrangement in the part of the NK 
complex between the genes encoding 
MICL and CLEC-1. In the non-primate 
arrangement CLEC-2 and CLEC9a show 
the same transcriptional orientation and 
CLEC9a contains the 6 common C-type 
lectin-like exons. Duplication of 5 CLEC-
2 exons followed by the inversion of the 
region encoding CLEC-2 and CLEC12b 
could have resulted in the opposite 
orientation of CLEC-2 and CLEC9A and 
the addition of three upstream exons to 
CLEC9A in primates. 
 
The myeloid cluster of the human NK complex seems to be a genomic region 
showing a high evolutionary activity in more recent times indicated by the 
AluS/AluJ ratio of 5,25 (147 AluS and 28 AluJ), which is relatively high as 
compared to the whole genome ratio of 3 (Trowsdale, Barten et al. 2001). AluJ 
repeats being the evolutionary oldest subfamily diverged 60 million years ago 
from a common source element, whereas the AluS subfamily was active about 
30 million years ago in the ancestral human genome after its divergence from 
rodents (Price, Eskin et al. 2004; Kapitonov and Jurka 1996; Kumar and 
Hedges 1998). It is further of interest to note that this region harbours as many 
AluY, which are the most recently active (24 million years ago) Alu repeats 
(Carroll, Roy-Engel et al. 2001), as AluJ elements.  
Despite the movement of the Alu sequences, the order and orientation of most 
genes in the myeloid cluster seem to be preserved between mice and men 
except in the relatively small region of about 40kb containing the CLEC-2 and 
CLEC12B genes. It was thus of interest to determine the order of the genes of 
the corresponding myeloid clusters of the syntenic regions in other species 
such as chimp, rhesus monkey, dog, cow and rat. Interestingly, as shown in 
figure 30 the gene order and orientation was found to correspond to the human 
complex only in primate genomes, while those of the other species were similar 
to the murine NK receptor complex.  
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Additionally, in the primate complexes, sequences highly homologous to five 
exons of CLEC-2 were found in the genomic region directly upstream of the 
coding region of CLEC9A (CLEC-2 exon 2: 96%, CLEC-2 exon 3: 91%, CLEC-2 
exon 4: 90%, CLEC-2 exon 5: 87%, CLEC-2 exon 6: 88%). This suggests that a 
duplication of exons 2-6 of the CLEC-2 gene followed by an inversion of the 
region containing the complete CLEC-2 and CLEC12B genes has taken place 
in a common primate ancestor (figure 30).  
Interestingly, sequences highly homologous to parts of the CLEC2 gene were 
also found in the 5’-UTR of CLEC9A mRNA (AY358265) indicating that 
upstream non-coding exons 1 and 3 of CLEC9A are derived from intronic 
regions while exon 2 is derived from the second CTLD exon of an ancestral 
CLEC2 gene. These three exons upstream of the coding region of CLEC9A 
form a 5’-UTR of about 640bp which contains an open reading frame (ORF) of 
273bp starting at position -362bp and ending at position -87bp relative to the 
CLEC9A translation initiation site. Since mini ORFs in the untranslated region of 
several genes have been shown to interfere with the translation of the 
corresponding proteins (Geballe and Morris 1994; Parola and Kobilka 1994; 
Garnier, Circolo et al. 1995) it is of interest to note that a putative internal 
ribosomal entry site (IRES) could be identified directly 5’ of the start codon 
(position –93 to –1). This putative IRES could mediate 5`-end-independent 
ribosomal attachment to an internal position in the mRNA and could thereby 
facilitate CLEC9A translation as was shown for other genes (Hellen and Sarnow 
2001). 
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3.4.3) Exon-intron structure of the additional genes 
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Figure 31: Exon-intron 
structures of the 
additional genes of the 
NK gene complex. The 
exon-intron structures 
for the additional genes 
of the NK gene complex 
were analyzed by 
aligning the mRNA 
sequences of the genes 
to the corresponding 
genomic region. The 
protein domains were 
identified and assigned 
to the exons by SMART-
analysis. A: Exon-intron 
structures of the 
additional genes 
encoding the lectin-like 
proteins CLEC12B, 
CLEC9A and NKG2i. B: 
Exon-intron structures of 
the additional genes 
encoding non-lectin-like 
proteins FLJ31166 and 
GABARAPL1. C: 
Alternative splicing of 
murine CLEC9a in 
comparison to human 
DECTIN-1. 
 
Most of the proteins encoded in the myeloid cluster of the NK gene complex are 
lectin-like receptors characterized by a type II transmembrane orientation and 
three C-type lectin-like domains encoded by three exons (Drickamer 1999). 
Based on an analysis of the exon-intron structure and of the potential protein 
domains and motifs, the four additional genes and proteins can be classified 
into two distinct subgroups (figure 31A, 31B). 
The first group of genes indeed encodes lectin-like receptors that show the 
typical exon-intron structure consisting of six exons coding for a N-terminal 
cytoplasmic region, a transmembrane region, a neck and three C-type lectin-
like domains (Drickamer 1999). The intron-exon structure as well as the 
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predicted protein structure of CLEC12B fits the canonical lectin-like structure, 
although at least four human CLEC12B mRNA and EST sequences have been 
found in sequence databases (NCBI) indicating that CLEC12B is differentially 
spliced. 
The mRNA sequence of human CLEC9A contains three untranslated upstream 
exons in addition to the six exons common to all C-type lectins. As noted before 
the second UTR exon shows a striking homology of 90% to the first CTLD exon 
of CLEC-2. Sequences homologous to the other two CTLD exons, the 
transmembrane and the neck domain of CLEC-2 as well as the corresponding 
intron and 3’UTR regions were detected in the genomic sequence between 
UTR exon 1 and UTR exon 3 of the CLEC9A upstream region. 
In contrast to human CLEC9A, no additional upstream exons could be identified 
in murine CLEC9a. However, murine CLEC9a contains two neck exons and two 
alternatively spliced mRNAs have been reported. The first splice variant shows 
the common C-type lectin-like exon-intron structure with a single neck domain, 
whereas the second splice variant contains both exons leading to an extended 
neck domain in the corresponding protein. As shown in figure 31C this 
alternative splicing event causing an incorporation of the second neck exon or 
not, is probably due to a mutation from GT to GC at the 5’-splice site of intron 4, 
which renders this splice site less efficient as compared to a AG/GT site. A 
similar mutation at the 5’-splice site of exon 3 probably leads to an alternatively 
spliced mRNA lacking the stalk exon in DECTIN-1 (Sobanov, Bernreiter et al. 
2001).   
Importantly, the other two additional genes found in the myeloid cluster, 
FLJ31166 and GABARAPL1, do not code for lectin-like receptors. For human 
and murine FLJ31166 transmembrane regions, but no other protein domains or 
homologies to other proteins could be detected. The exon-intron structure of 
human und murine GABARAPL1 is made up of four coding exons and the 
protein does not contain a transmembrane region. The first exon has been 
reported to encode a tubulin binding site, whereas the sequence of exon three 
and four codes for a GABA receptor binding site (Xin, Yu et al. 2001). 
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3.4.4) Amino acid sequences of the additional lectin-like proteins 
 
 
 
Figure 32: Amino acid sequence of the additional proteins in comparison to known lectin-like 
receptors. The amino acid sequences of the human and murine homologs of the additional lectin-like 
proteins CLEC12A and CLEC9A in comparison to the known lectin-like receptors CLEC-1, CLEC-2 and 
DECTIN-1 are shown. The proteins were aligned using the ClustalW algorithm of the MacVector software. 
Identical and similar amino acids are marked by boxes. Filled grey boxes indicate identical amino acids. 
Red boxes highlight ITAM-like motifs in the cytoplasmic part and the highly conserved cysteins in the 
CTLD, respectively. 
 
The amino acid sequences of lectin-like receptors share common 
characteristics, such as six highly conserved cystein residues in the 
extracellular part of the protein and some also contain motifs involved in Ca2+- 
and ligand binding, namely EPN (mannose binding) / QPD (galactose binding) 
and WND (Drickamer 1999; Zelensky and Gready 2005). The human and 
murine homologs of the additional lectin-like proteins CLEC12B and CLEC9A 
show most typical features of lectin-like receptors. Both proteins in human and 
mice contain the 6 conserved cystein residues in the first and in the third CTLD, 
as well as an ITAM-like YXXL-motif in the cytoplasmic tail. This cytoplasmic 
motif is highly similar to motifs found in the cytoplasmic region of DECTIN-1 and 
CLEC-2 which have been shown to be essential in DECTIN-1-mediated 
phagocytosis of Zymosan (Herre, Marshall et al. 2004) and in CLEC-2 mediated 
platelet activation (Suzuki-Inoue, Fuller et al.) (figure 32).  
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Similar to most of the other C-type lectin-like proteins of the myeloid cluster, 
which do not contain known motifs involved in Ca2+- or sugar binding, no such 
pattern could be identified in CLEC12B and CLEC9A. The only exception in the 
myeloid cluster is DECTIN-1, which contains one QPD motif. Although these 
motifs are characteristic for sugar binding and even indicate whether mannose 
or galactose is bound, their absence does not rule out that the corresponding 
receptor binds sugars (Zelensky and Gready 2005). 
No significant sequence similarities were detected between the lectin-like 
receptors and FLJ31166 or GABARAPL1 (data not shown). Moreover, these 
two genes do not share any common characteristics and appear evolutionary 
not related.  
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3.4.5) Evolutionary relationship between the lectin-like receptors 
 
 
 
Figure 33: Phylogenetic tree of the genes of the human and mouse NK gene complex based 
on the CTLD sequences. The phylogenetic tree showing the evolutionary relationship between 
CLEC12B, CLEC9a and other lectin-like proteins of the NK gene complex. The CTLD parts of the 
amino acid sequences displayed in figure 3 as well as additional sequences of the human and 
murine NKG2 gene family were used to construct this phylogenetic tree using the ClustalW 
algorithm provided by EMBL/EBI (www.ebi.ac.uk/clustalw/). Additional genes boxed in red, myeloid 
subfamily encircled in green.  
 
To reveal the evolutionary relationship of the additional lectin-like receptors 
CLEC12B, CLEC9A (and murine NKG2i) to the other C-type lectin-like proteins 
encoded in the centromeric part of the NK gene complex, a phylogenetic tree 
based on the amino acid sequences of the CTLD was constructed (figure 33). 
These C-type lectin-like receptors clearly fall into two separate groups, namely 
the myeloid and NK receptor groups, and CLEC9A and CLEC12B clearly 
belong to the myeloid subfamily. The tree furthermore shows that CLEC12B is 
most closely related to DECTIN-1. CLEC9A is similarly high related to CLEC-1,  
DECTIN-1 and CLEC12B.  mNKG2i on the other hand is most highly related to 
mNKG2e and is clearly a member of the NK-receptor subfamily. Thus the 
relationship displayed by the phylogenetic tree corresponds to the arrangement 
of the receptors in the NK gene complex (see figure 29). It is of interest to note, 
that in the myeloid subgroup the sequences of the human receptors show 
highest homology to their murine homologues whereas the human NKG2A, C 
E 
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and E receptors appear to show higher homology with each other than with the 
murine homologues, providing an example for convergent evolution of these 
three receptor chains. 
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3.4.6) Expression of the additional lectin-like genes CLE12B and 
CLE9A  
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Figure 34: Expression of additional genes in various cell types. Expression levels of the 
additional lectin-like genes were measured using quantitative Real-Time RT-PCR. Absolute 
amounts of copies of cDNA were calculated by using standardized amounts of cloned templates. 
Values obtained for the individual mRNAs were normalized to the corresponding values obtained for 
β2-microglobulin as internal control and are expressed as molecules / 106 molecules β2-
microglobulin. Shown are the mean values (± SD) of at least two independent experiments 
performed in triplicate. A: Schematic representation of splicing events resulting in the four splice 
variants A to D of CLEC12B (detected by PCR) and the domain structure of the corresponding 
protein obtained using SMART (available at http://smart.embl-heidelberg.de/smart), vertical blue 
box: transmembrane region, horizontal green box: coiled coil domain, pink CLECT box: C-type 
lectin-like domain.  B: Expression levels of CLEC12B splice variants A and B in various cell types. C: 
Expression levels of CLEC9A in in various cell types. 
 
A 
 
B 
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The genes encoded in the human NK receptor complex can be subdivided into 
two groups according to their expression pattern. The genes of the NKG2/CD94 
subfamily are expressed predominantly on NK cells and some on NKT and 
subpopulations of T cells. In contrast the genes of the myeloid subfamily are 
expressed on myeloid cells and some on endothelial cells. It was therefore of 
interest to investigate the expression of the genes newly annotated to the NK 
receptor complex in cells of various lineages of haematopoietic origin using 
quantitative Real-Time RT-PCR. GABARAPL1 was found in all cell types 
tested, whereas expression of FLJ31166 could not be detected in any of the 
cells (data not shown). 
Expression of the C-type lectin-like gene CLEC9A was very low (<100 
molecules / one million molecules of β2-microblobulin) in DC, HUVEC, the NK 
cell line NK-92, the monocytic cell line U-937 and the myeloid-erythroid line K-
562. CLEC9A expression was higher (>300 molecules / one million molecules 
of β2-microglobulin) in the B lymphoid line RPMI 8866, the B-lymphoblastoid 
line 721.221 and the T cell line Jurkat. The highest levels of expression were 
detected in the monocytic line Mono-Mac-6 and the T cell line CCRF-CEM 
(figure 34C) 
Using PCR to isolate the complete cDNA of CLEC12B from PBMC we found 
the mRNA of this molecule to be differentially spliced (figure 34A). Four different 
splice variants of CLEC12B were detected resulting from two independent 
differential splicing events. Splice variant A codes for a protein which shows the 
canonical lectin-like structure of an intracellular domain, a transmembrane 
domain and a stalk domain encoded by one exon each followed by three exons 
coding for three CTLD. A differential splicing event at the 3’-end of the second 
CTLD exon leads to an extension of this exon which contains a stop codon 
giving rise to a protein lacking the last of the three CTLD. A second differential 
splicing event does not join the transmembrane coding exon to the 5’-end of the 
stalk exon but instead uses a potential splice site 8 bp further downstream in 
the stalk exon. This causes the deletion of 8 bp of the mRNA resulting in a 
frame shift and the immediate stop of translation. The putative resulting protein 
contains only the cytoplasmatic and transmembrane domains. Since these 
differential splicing events also give rise to truncated, potentially non-functional 
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proteins it was of interest not only to determine the overall expression levels of 
CLEC12b but also to discriminate especially between putative functional and 
non-functional isoforms using different sets of primers. Isoforms A and B of 
CLEC12B are not expressed by HUVEC, the myeloid-erythroid line K-562, the 
B cell lines 721.221 and RPMI 8866, and the NK cell line NK-92. Low 
expression could be detected in DC, the monocytic lines U-937 and Mono-Mac-
6 and the T-lymphocyte line Jurkat. The T-lymphocyte line CCRF-CEM 
expressed the highest levels of mRNA. In general, the majority of the transcripts 
detected in these cells contain the 8 bp deletion in the stalk exon probably 
rendering the translated product non-functional (data not shown). Only CCRF-
CEM cells express substantial levels of CLEC12B mRNA that probably codes 
for a functional protein (figure 34B). Thus it seems that CLEC12B and CLEC9A 
do not display the myeloid-specific expression observed for CLEC-1, CLEC-2 
and DECTIN-1, but rather are more broadly expressed in the myeloid as well as 
the lymphocyte lineage. 
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3.4.7) Regulation of the additional lectin-like genes in dendritic cells. 
 
    
 
 
 
 
 
 
 
Figure 35: Regulation of lectin-like receptors in dendritic cells. Dendritic cells (DC) generated from 
CD34+ cells isolated from cord blood were stimulated using LPS, Zymosan, anti-CD40 and IFNγ. 
Expression levels of the additionals genes were measured using quantitative Real-Time RT-PCR. Absolute 
amounts of copies of cDNA were calculated by using standardized amounts of cloned template. Values 
obtained for the individual mRNAs were normalized to the corresponding values obtained for β2-
microglobulin as internal control and are expressed as molecules / 106 molecules β2-microglobulin. Shown 
are the mean values (± SD) of at least two independent experiments performed in triplicate.  
 
The C-type lectin-like receptors CLEC-1, CLEC-2 and DECTIN-1 are known to 
be expressed in dendritic cells (Colonna, Samaridis et al. 2000; Sobanov, 
Bernreiter et al. 2001; Delneste, Magistrelli et al.) and DECTIN-1 has been 
shown to be downregulated upon activation of DC (Sobanov, Bernreiter et al. 
2001; Delneste, Charbonnier et al.). We therefore investigated the regulation of 
CLEC12B and CLEC9A in comparison to DECTIN-1, CLEC-1 and CLEC-2 in 
DC after treatment with various maturation stimuli. To this end DC derived from 
CD34+ cord blood cells were treated with 100 ng/ml LPS, 25 µg/ml Zymosan A, 
4 µg/ml anti-CD40 mAb cross-linked by F(ab')2-fragments of goat anti-mouse 
IgG and 10 ng/ml INFγ for 6 hours and mRNA levels were measured using 
Real-Time RT-PCR. Stimulated cells were kindly provided by Dr. Frank Kalthoff 
(Novartis, Austria).  
As expected stimulation of these cells with any of the stimuli used led to a clear 
downregulation of DECTIN-1. Similar to DECTIN-1, the expression of CLEC-2 
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was downregulated upon stimulation of DC, however to a lesser extent. CLEC-1 
expression on the other hand was only significantly effected in DC stimulated 
with either LPS or Zymosan but not with anti-CD40 antibody or INFγ.  
In contrast, neither expression of CLEC9A nor CLEC12B was significantly 
altered by treatment of DC with any of the maturation inducing stimuli used 
(figure 35).  
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4) Discussion 
 
4.1) CLEC-1 and CLEC-2 are expressed in myeloid cells of 
PBMC 
 
CLEC-1 and CLEC-2 together with DECTIN-1 and LOX-1 are members of the 
myeloid subfamily of genes encoded in the NK receptor complex. The first 
genes identified to be encoded in this complex were found to be specifically 
expressed in NK and NKT cells, such as the NKG2A, -C and -E genes, which 
encode inhibitory and activating NK receptor chains. Unlike the NKG2 receptors 
CLEC-1 and CLEC-2 are not expressed on NK cells, but show a much broader 
expression pattern. CLEC-2 seems to be restricted to leukocytes, but CLEC-1 
mRNA was also found in endothelial cells (Sobanov, Bernreiter et al. 2001; 
Colonna, Samaridis et al. 2000). As there were no consistent and comparable 
expression data available for CLEC-1 and CLEC-2 for different blood cell types, 
the aim of the expression studies was to give a comprehensive overview of the 
expression of these receptors in the different subtypes of immune cells from 
peripheral blood.  
In our analysis, the presence of CLEC-2 mRNA was detected in total PBMC, 
granulocytes and platelets. In addition, we found CLEC-2 mRNA in the CD14+ 
(CD nomenclature see Appendix C) monocytic fraction of PBMC, although the 
mRNA level was only about one tenth of the level in granulocytes. There was 
no detectable CLEC-2 mRNA in CD3+ and CD19+ lymphocytic fractions of 
PBMC. In line with the mRNA data, flow cytometry analysis displayed CLEC-2 
on platelets and monocytes. However, despite clear presence of CLEC-2 
mRNA in granulocytes, there was no detectable surface expression on this cell 
type, suggesting additional levels of control either at translation, protein stability 
or transport to the surface. CLEC-2 mRNA expression in monocytes 
corresponds with previous reports, which described  CLEC-2 mRNA in liver and 
in blood cells of myeloid origin, including monocytes, granulocytes, and 
dendritic cells (Colonna, Samaridis et al. 2000). However, protein expression 
was until now only reported for platelets, where it had been shown to function in 
platelet activation (Suzuki-Inoue, Fuller et al. 2006).  
-98- 
CLEC-1 mRNA was found at a similar level in granulocytes and CD14+ 
monocytes and as for CLEC-2 no expression could be detected in CD3+ T-
lymphocytes and in CD19+ B-lymphocytes. In contrast to CLEC-2, platelets did 
not contain significant amounts of CLEC-1 mRNA. Whereas CLEC-2 was  
expressed on the surface of cells containing CLEC-2 mRNA, with the exception 
of granulocytes, CLEC-1 could not be detected on the surface of any cell 
despite clear presence of CLEC-1 mRNA. Similarily, ectopically expressed 
recombinant CLEC-2 was transported to the cellular surface, whereas CLEC-1 
produced from viral vectors in endothelial cells did not lead to detectable 
surface expression, in spite of a high intracellular accumulation of the protein 
with an endoplasmic reticulum-like pattern. 
The obvious discrepancy between the presence of mRNA on the one hand and 
the absence of surface protein expression on the other hand could have been 
caused by translational control, protein instability or the lack of transport to the 
cell surface. For example, negative translational control of mRNA could take 
place at any step during protein translation either by regulatory proteins or 
microRNA recognizing specific motifs present in the 5’ and/or 3’UTR (Gebauer 
and Hentze 2004). Already translated protein could be degraded immediately or 
could accumulate in intracellular membranes and be prevented from being 
transported to the surface. As a case in point, SNAT2 has been demonstrated 
to move from an endosomal fraction to the surface in myocytes and adipocytes 
only after stimulation with insulin (Hyde, Christie et al. 2001; Hyde, Peyrollier et 
al. 2002). Further, PCR analysis can not exclude the possibility, that the 
detected transcripts are incomplete splice variants or lack any of the essential 
structural and regulatory features needed for effective translation. In the case of 
viral-mediated expression, intracellular retention could also be due to an 
overexpression artifact. The enormous expression of a recombinant protein 
could overwhelm the protein transport machinery or cause insufficiencies in the 
availability of a potentially needed surface expression partner. 
In the case of the absence of CLEC-2 protein on the surface of granulocytes 
our experiments suggest either a translational block or a rapid protein 
degradation, as granulocytes do also not contain detectable amounts of 
intracellular CLEC-2 protein. Furthermore, ectopic expression of CLEC-2 in 
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endothelial cells leads to immediate strong surface expression arguing against 
any problems connected with the surface transport of CLEC-2.  
CLEC-1 on the other hand seems to be deficient for surface transport and to be 
a constituent of intracellular membranes. This is supported by the fact that 
ectopically expressed CLEC-1 does not reach the cellular surface in endothelial 
cells. Further, endogenous CLEC-1 protein could be clearly localized to 
intracellular membranes in endothelial cells as discussed in more detail below. 
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4.2) Peripheral blood monocytes display CLEC-2 surface 
expression 
 
During our analysis of blood cell subsets, CLEC-2 could be identified on primary 
CD14+ monocytes on mRNA as well as on protein level. This might be of 
relevance as CLEC-2 has been recently reported to bind to podoplanin, a highly 
O-glycosylated type-1 transmembrane protein, which is expressed on lymphatic 
but not on blood vessel endothelium. It is therefore widely used as a specific 
marker for lymphatic endothelial cells (Breiteneder-Geleff, Soleiman et al. 
1999). Podoplanin has further been identified in a wide variety of healthy 
tissues such as kidney, skeletal muscle, placenta, lung and heart (Breiteneder-
Geleff, Soleiman et al. 1999; Martin-Villar, Scholl et al. 2005) and shown to be 
upregulated in several human cancers (Martin-Villar, Scholl et al. 2005; 
Schacht, Dadras et al. 2005; Shibahara, Kashima et al. 2006; Wicki, Lehembre 
et al. 2006).  
So far, CLEC-2 has been mainly decribed to function as activating receptor on 
peripheral blood platelets (Suzuki-Inoue, Fuller et al. 2006). In a pathologic 
situation it is thought that interaction between podoplanin on tumour cells and 
CLEC-2 on platelets is capable of regulating tumour metastasis, invasion and 
growth by inducing platelet activation and aggregation on the tumour cell 
surface (Kato, Kaneko et al. 2008). In normal physiological conditions it is still 
unknown whether an interaction between podoplanin on lymphatic endothelium 
and CLEC-2 on platelets plays an important role. Podoplanin is only expressed 
on lymphatic endothelial cells, but not on blood endothelial cells and it is 
unclear under which conditions platelets would come in contact with the 
lymphatics (Suzuki-Inoue, Kato et al. 2007). Podoplanin-deficient mice show 
defects in lymphatic vessel pattern formation (Schacht, Ramirez et al. 2003), 
therefore it might be possible that podoplanin CLEC-2 interaction is important 
during organ development.  
Taking all this in consideration, it seems likely that CLEC-2 expressed on 
monocytes might be an interaction partner for podoplanin on lymphatic 
endothelial cells, e.g. mediating homing of monocytes to the lymphatics or, in a 
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pathologic situation, recruitment of monocytes to podoplanin-expressing 
tumours.  
Several PBMC and CBMC samples obtained from healthy volunteers were 
therefore tested for CLEC-2 expression on their monocytic fraction. In general it 
was found that CLEC-2 expression was more prominent in PBMC than in 
CBMC monocytes, although there was a clear donor-dependent variation in the 
percentage of monocytes with CLEC-2 expression. Whereas most CBMC 
samples tested were negative or only partly positive for CLEC-2, two thirds of 
all PBMC samples tested were classified to be strong expressers with more 
than 20% of monocytes being positive for CLEC-2. Generally, different samples 
seemed to differ in the percentage of monocytic cells displaying CLEC-2 
staining rather than in the strength of the signal. The data are compatible with 
the possibility that usually a subpopulation of peripheral monocytes expresses 
CLEC-2 and the size of this subpopulation varies depending on the donor. 
Furthermore, not only different donors showed differences in the expression 
level of CLEC-2, but also single donors tested at different times displayed 
significant variation. It is conceivable that this variation is explained by the 
infection status of the donor, causing monocytes to up- or downregulate CLEC-
2 surface expression. This hypothesis would also be in line with the fact that 
CBMC monocytes showed low CLEC-2 expression, as monocytes from cord 
blood samples are unlikely to have already been exposed to infections.  
Western blotting clearly confirmed the presence of CLEC-2 in monocytes, 
although at a lower level as compared to platelets.  
To obtain further clues about the potential importance of CLEC-2 expression on 
monocytes, we investigated adhesion of CLEC-2 expressing blood cell subsets 
on different podoplanin expressing cell monolayers. We used MCF-7 cells 
stably transfected to overexpress podoplanin and lymphatic endothelial cells 
expressing podoplanin at physiological levels. For adhesion we used DiO-
labeled CD14+ monocytes, whole PMBC, lymphocytes, granulocytes, platelets 
and K-562 overexpressing CLEC-2 as positive control. As expected we found 
that CLEC-2 expressing platelets showed a clear adhesion to podoplanin+ 
MCF-7 cells as well as to LEC.  In line with the findings that lymphocytes and 
granulocytes do not express CLEC-2 on their surface, no specific adhesion of 
lymphocytes and granulocytes to podoplanin expressing cells was detecetd. 
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Probably due to the low CLEC-2 expression levels, no clear adherence of 
monocytes to podoplanin+ MCF-7 could be shown, although a tendency of 
monocytes to adhere slightly stronger to LEC as to HUVEC may be revealed, 
but would need further evaluation.  
As the interaction between CLEC-2 and podoplanin has been reported to have 
a dissociation constant of 24,5 µM suggesting a weak affinity interaction 
(Christou, Pearce et al. 2008), the lack of binding could be explained by a too 
low binding avidity in the in vitro assay due to the low CLEC-2 expression on 
monocytes. Nevertheless this low expression could potentially be sufficient for 
an interaction of monocytes and lymphatic endothelium in vivo. 
In summary, this work has supplied clear evidence for CLEC-2 expression on 
primary CD14+ monocytes, on mRNA level as well as on protein level. 
However, protein expression levels were found to be variable and the rather low 
expression will require additional in vivo data to reveal the functional 
implications of CLEC-2 expression by monocytes, e.g. in corresponding CLEC-
2 and podoplanin knock-out mice. Nevertheless, the expression of CLEC-2 on 
monocytes suggests an additional contact and homing pathway for monocytes 
to lymphatic endothelium.
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4.3) CLEC-1 is localized intracellularly in endothelial cells 
 
CLEC-1 shows high homology to CLEC-2 and to the other receptors of the 
myeloid subfamily of the NK gene complex and in bioinformatic analysis 
displays all characteristics of a functional type II C-type lectin-like receptor, i.e. 
a signal anchor, a transmembrane region and three C-type lectin-like domains. 
It further harbours a predicted coiled coil region adjacent to the transmembrane 
domain, matching the neck region of C-type lectins. The model of the CLEC-1 
tertiary structure based on the homology to the DC-SIGN sequences shows 
high similarity to the structures of already crystallized family members, such as 
CLEC-2. Protein sequence analysis further detected regions of intrinsic 
disorder, which had been reported to be involved in regulation, signaling and 
control pathways (Uversky, Oldfield et al. 2005; Iakoucheva, Brown et al. 2002; 
Dunker, Cortese et al. 2005). These regions in CLEC-1 could be detected on 
the very N-terminus and are probably involved in interacting with partners of the 
downstream signaling cascade as well as on the very C-terminus possibly 
involved in ligand binding.  
Considering a possible signaling function, the CLEC-1 cytoplasmic region does 
contain an ITAM-like motif highly similar to DECTIN-1, although DECTIN-1 has 
been shown to signal exclusively via another ITAM-like motif closer to the 
transmembrane region (Herre, Marshall et al. 2004), which is shared with 
CLEC-2 and other members of the family but not present in CLEC-1. A putative 
signaling function of CLEC-1 remains therefore uncertain. It could be that 
CLEC-1 has lost its signaling capacity and might be a non-functional protein 
which has acquired additonal mutations leading to a lack of surface expression. 
However, the observed 50 to 75% conservation of the CLEC-1 coding 
sequences between species as far apart as humans and rodents strongly 
suggests a protein with an important function. In addition, considering that 
genes of the immune system usually evolve faster than common genes, this 
degree of conservation is even more striking (Uhrberg 2005; Hughes and 
Yeager 1997).  
Taken together all this evidence supports that CLEC-1 might be a functional 
protein that should be inserted into cellular membranes with a putative role as 
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surface receptor. However, although significant levels of mRNA were detected 
in different blood cells as well as in endothelial cells, CLEC-1 could not be 
detected on the surface of any cell tested. Furthermore, recombinant CLEC-1 
expressed from adenoviral vectors would only accumulate intracellularly and did 
not reach the cell surface.  
It was also conceivable, that CLEC-1 would require a special stimulus to be 
transported to the cell surface, we therefore triggered endothelial cells with the 
pro-inflammatory stimuli TNF-α, LPS and PMA and tested for CLEC-1 
relocalisation to the cell surface. In addition ligands of TLRs and infection of the 
cells with selected pathogens was tested to reveal any potential relocalization 
within or towards the surface of the cell. However, none of the stimuli tested led 
to surface exposure or any other relocalization of CLEC-1.   
Therefore we started to consider the possibility that the cellular surface may not 
be the physiological location of CLEC-1 within the cell. However, considering 
the presence of a transmembrane region as well as a type II signal anchor in 
CLEC-1, the integration into an intracellular membrane was likely.  
Indeed, fractionation of endothelial cells known to express endogenous CLEC-1 
into cytoplasmic, membrane and nucleic fraction and subsequent analysis of 
these fractions by Western blotting confirmed the proposed membrane-bound 
localisation of the protein. Further, immunofluorescence staining of CLEC-1 
done in comparison to surface-localized CLEC-2 and markers of the 
endoplasmic reticulum (ER) and the golgi apparatus, clearly showed that 
CLEC-1 staining was highly similar to the pattern of ER resident proteins. There 
was clearly no golgi-like expression and no surface expression comparable to 
CLEC-2 staining.  
To further specify the intracellular localisation of CLEC-1 to the endoplasmic 
reticulum, we used differential centrifugation of endothelial cell lysates for 
preparing fractions enriched in cytoplasmic, mitochondrial, lysosomal, 
microsomal and nucleic proteins. CLEC-1 again was most prominently present 
in the ER fraction displaying similar staining as the ER protein calnexin 
supporting an integration of the protein into endoplasmic reticulum membranes. 
As expected there was clearly no CLEC-1 detected in the cytoplasm as well as 
in the nucleus, although some CLEC-1 was detectable in the mitochondrial and 
lysosomal fractions, probably due to unsufficient purity of the fractions. It is 
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known, that ER resident proteins are localized within the ER because they are 
actively prevented from entering the secretory pathway by retention and 
retrieval signals. The classical retention signal for luminal ER proteins such as 
protein disulfide isomerase (PDI) is a Lys-Asp-Glu-Leu (KDEL) sequence (Luz 
and Lennarz 1996), whereas most integral membrane proteins such as the 
chaperon calnexin carry positively charged cytosolic residues like a KKXX 
(where X is any amino acid) motif (Nilsson and Warren 1994; Andersson, 
Kappeler et al. 1999). Simple sequence analysis did not reveal a classical motif 
which could fulfill such a function in CLEC-1, but as it has been proposed for 
other proteins like LMF1 (Lipase maturation factor 1) its location within the ER 
may be ensured by interaction with ER proteins possessing a retention signal 
(Péterfy 2008). 
The data thus obtained using recombinant overexpressd CLEC-1 as well as 
studying endogenous CLEC-1 in endothelial cells strongly support that CLEC-1 
may have an intracellular localization and function. It is likely an intracellular 
member of the myeloid family of pattern recognition receptors of the NK gene 
complex. In this regard CLEC-1 could be compared to the intracellular Toll like 
receptors TLR 3, 7 and 9 which recognize microbial nucleic acids such as 
double-stranded RNA (TLR 3) (Alexopoulou, Holt et al. 2001), single-stranded 
RNA (TLR 7 and 8) (Diebold, Kaisho et al. 2004) and non-methylated CpG-
containing DNA (TLR 9) (Hoene, Peiser et al. 2006). TLR9 for example has 
been shown to be expressed in the endoplasmic reticulum but to be relocalized 
to lysosomes upon activation of the cell by CpG-ODN (Latz, Schoenemeyer et 
al. 2004). Given the similarities in localization we decided to test whether 
ligands of intracellular Toll like receptors or other pro-inflammatory stimuli would 
show effects on CLEC-1 expression or in terms of preferential ER or lysosomal 
localization. However, intracellular relocalisation of CLEC-1 in dendritic cells 
overexpressing CLEC-1 could not be detected upon stimulation with any of the 
reagents tested  including CpG-ODN, poly(I:C) and Imiquimod. However, Real-
Time RT-PCR using cDNA preparations of stimulated dendritic cells revealed a 
downregulation of CLEC-1 mRNA upon poly(I:C), CpG, TNF-α, LPS and PMA 
stimulation, whereas incubation with imiquimod did not show any significant 
effect. The absence of downregulation following imiquimod treatment is in 
contrast to the downregulation pattern observed for other receptors of the family 
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such as DECTIN-1, which is efficiently downmodulated by imiquimod as well. It 
remains to be seen whether this could indicate a role of CLEC-1 in the 
response to single-stranded RNA viruses. At the moment the general pattern of 
downregulation in dendritic cells might rather suggest that the effect is not 
specific for CLEC-1 but is a common effect of maturation of the dendritic cells. 
Upon encounter of pathogens, dendritic cells start to mature initiating the 
downregulation of receptors no longer needed for antigen uptake, whereas on 
the other hand receptors for migration to lymph nodes and antigen presentation 
are upregulated. Although the downregulation of CLEC-1 upon dendritic cell 
maturation does not define a specific role in the process of pattern recognition it 
could be taken as evidence compatible with a function of CLEC-1 in the process 
of pathogen detection in the immature stages of DC. 
Given the intracellular localization of CLEC-1 it appeared possible that CLEC-1 
could play a role in the response to intracellular pathogens. We therefore 
investigated whether CLEC-1 would be able to bind to selected examples of 
eucaryotic and procaryotic intracellular parasites, namely Toxoplasma gondii 
and Listeria monocytogenes. We isolated both Toxoplasma gondii and Listeria 
monocytogenes and tested on the one hand the direct binding of soluble CLEC-
1 to the isolated pathogens and on the other hand intracellular (co)localization 
of CLEC-1 with the pathogens in infected cells. However, CLEC-1 neither 
bound the isolated parasites or bacteria in a way similar to the binding of yeast 
cell walls by DECTIN-1 nor could we detect any signs of interaction, e.g. 
accumulation of CLEC-1 around sites of infection within infected cells. Thus, it 
appears that CLEC-1 is not involved in the response to Toxoplasma gondii and 
Listeria monocytogenes and a definition of the function of this protein will likely 
have to await serial testings of a large number of additional candidates.
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4.4) The myeloid subfamily of the NK gene complex contains 
additional lectin-like genes 
 
The centromeric part of the NK-gene complex contains two different subgroups 
of genes. One subfamily of C-type lectin-like receptor genes comprises the 
NKG2 and CD94 genes, which are expressed on NK, NKT and some T cell 
subpopulations (Hofer, Sobanov et al. 2001). The genes localized more 
telomeric in the centromeric half of the complex are more broadly expressed, 
preferentially by cells of the myeloid lineage (Hofer, Sobanov et al. 2001). The 
members of these two subfamilies do not only show similar expression patterns 
but also share the highest sequence similarities within each family. 
Furthermore, the genomic distances between the genes of one subfamily are 
short, whereas the stretch of non-coding sequences physically separating the 
myeloid from the NK subfamily, is much longer, suggesting that these families 
originated from consecutive gene duplications. 
In this work we concentrated on the myeloid cluster encoding among others 
genes identified in our laboratory (Sobanov, Bernreiter et al. 2001).  
In the human complex two additional C-type lectin-like genes, CLEC9A and 
CLEC12B, were shown to be encoded between CLEC-1 and CLEC-2. Because 
of their location and high sequence homology to the neighbouring receptors of 
the myeloid cluster, both genes clearly are members of the myeloid subgroup. 
Like the other receptors of the myeloid cluster of the NK receptor complex, the 
CLEC9A and CLEC12B genes have orthologues in the murine genome and 
were therefore probably already present in a common human-murine ancestral 
genome. 
In addition to CLEC12B and CLEC9A, two genes not coding for C-type lectin-
like proteins, FLJ31166 and GABARAPL1, were identified between the two 
subgroups but in close proximity to the centromeric end of the myeloid cluster. 
The proteins encoded by those genes do not show any homology to the lectin-
like receptors of the myeloid cluster or to those of the NK cluster. These genes 
are also regulated differently from the other genes of the NK complex. 
FLJ31166 appears not to be expressed in cells of the haematopoietic lineage 
since we could not detect any mRNA, neither in any of the cell lines tested nor 
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in PBMC (data not shown). In contrast GABARAPL1 seems to be expressed 
ubiquitously in a variety of tissues (Nemos, Mansuy et al. 2003), including all 
haematopoietic cells tested (data not shown). This indicates that these genes 
stand apart from the lectin-like genes characterized in the NK gene complex. 
Another gene belonging to the NK receptor subfamily, NKG2i, is encoded 
telomeric of CD94 in the murine complex. The presence of this gene in the 
murine complex is a major difference between the human and the murine 
cluster, because the syntenic human region does not contain an NKG2i 
homolog. Instead, it displays an additional stretch of non-coding DNA of about 
60 kb showing no considerable homology to the murine cluster. As this region is 
only present in the human genome, this difference could have resulted either 
from an insertion into the human or a deletion from the murine sequence. The 
members of the NKG2 subfamily appear to have arosen from gene duplications 
of one single common ancestral sequence (Barten, Torkar et al. 2001), it might 
be that the murine NKG2i is the result of a relative recent duplication event, 
which did not occur in humans.  
Another prominent difference between the primate and the rodent cluster is an 
inversion between CLEC9A and MICL that causes the primate CLEC-2 and 
CLEC12B to display opposite transcriptional orientation as compared to their 
homologous in the other species investigated. As in addition a stretch of 
sequence upstream of the primate CLEC9A coding region shows high 
homology to CLEC-2 we suggest that this inversion took place after a partial 
duplication of the gene encoding CLEC-2 in the genome of a common primate 
ancestor.  
The additional genes CLEC9A and CLEC12B show all typical characteristics of 
C-type lectin-like genes as far as amino acid sequences, exon-intron structure 
and corresponding protein domains are concerned. CLEC9A is unusual as far 
as it contains three non-coding upstream exons, probably originating from 
duplication of part of the CLEC-2 gene. 
CLEC12B has been reported shortly after we finished our analysis to function 
as inhibitory receptor in macrophages by recruiting the phosphatases SHP-1 
and SHP-2 through its ITIM (immunoreceptor tyrosine-based inhibition motif) 
domain (Hoffmann, Schellack et al. 2007). Our analysis found CLEC12B to be 
differentially spliced. In addition to an mRNA coding for a regular lectin-like 
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protein three additional splice variants were identified resulting from two 
independent alternative splicing events. All these differential splicing events 
lead to truncations and probably non-functional proteins.  
Alternatively spliced isoforms have been described for other receptors of this 
complex. In particular mature mRNAs of DECTIN-1 and CD94 have been 
demonstrated to be generated by multiple splicing events leading to various 
isoforms of which some code for truncated and potentially non-functional 
proteins (Willment, Gordon et al. 2001; Gavino, Chung et al. 2005; Lieto, 
Maasho et al. 2006). Moreover, functional isoforms lacking the stalk exon of 
NKG2A, known as NKG2B, DECTIN-1 and CD94 have been shown to exist 
(Willment, Gordon et al. 2001; Furukawa, Yabe et al. 1998; Lieto, Maasho et al. 
2006). Curiously, in the case of CLEC12B these truncated mRNAs encoding 
probably non-functional proteins, constitute the majority of transcripts in most 
cell types tested. It is however possible that mRNAs coding for full length 
CLEC12B are transcribed only in certain cell types or upon certain stimuli not 
tested in this study. 
CLEC9A contains an ITAM-like motif in its cytoplasmic tail similar to that found 
in DECTIN-1 and CLEC-2. The same motif in DECTIN-1 has been shown to be 
essential in phagocytosis of Zymosan (Herre, Marshall et al. 2004), which 
results in the phosphorylation of the tyrosine residue of the YxxL motif. This in 
turn leads to recruitment of the spleen tyrosine kinase (Syk) which is then 
activated by phosphorylation (Rogers, Slack et al. 2005; Underhill, Rossnagle et 
al. 2005). This is similar to the ITAM-like motif in CLEC-2 which is involved in 
platelet activation and has also been implicated in recruitment and activation of 
Syk (Suzuki-Inoue, Fuller et al. 2006). It is therefore tempting to speculate that 
the ITAM-like motifs in CLEC9A may be involved in cellular activation. Indeed, 
very recent studies by Huysamen et al. showed that CLEC9A recruits Syk and 
mediates endocytosis (Huysamen, Willment et al. 2008).  
Because both CLEC12B and CLEC9A share all major characteristics with the 
other lectin-like receptors encoded by genes of the myeloid cluster it is possible 
that these proteins fulfil similar functions. However, the pattern of expression of 
these two genes shows some differences as compared to the other members of 
the myeloid subfamily. Although CLEC12B and CLEC9A are expressed in cells 
of the myeloid lineage similar to CLEC-1, CLEC-2 and DECTIN-1, highest 
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expression was detected in the T cell line CCRF-CEM. Moreover, neither 
CLEC12B nor CLEC9A expression is significantly downregulated upon 
stimulation of dendritic cells using different stimuli, a feature common to the 
other C-type lectin-like receptors of the myeloid subfamily. Thus these two 
genes may differ to some extent from the others of the subfamily displaying 
differences in cell type specific expression and regulation. For example,  
CLEC9A expression was recently described to be present specifically only on 
BDCA3+ dendritic cells and on a small subset of CD14+CD16- monocytes 
(Huysamen, Willment et al. 2008).  
In summary, we have identified additional genes in the human and murine NK 
receptor complex and have investigated their sequence characteristics, 
phylogenetic relationship and expression pattern. While two of these genes do 
not belong to the lectin-like receptor family, the other two clearly are members 
of the myeloid subfamily of C-type lectin-like receptors based on sequence 
homology and expression patterns. 
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6) Appendix 
 
A: List of buffer ingredients  
 
buffer ingredients 
Blocking buffer (Western Blot)or 
 
5% BSA (w/v) 
0,5% skim milk powder (w/v) 
0,1% Tween 20 (v/v) 
in PBS 
Blotting buffer (Western Blot) 25mM Tris-HCl 
192mM glycine 
20% methanol (v/v) 
Dialysis buffer (Adenovirus 
generation) 
40% glycerin (v/v) 
20mM HEPES 
50mM NaCl 
Et3N buffer (Cell Fractionation) 250mM sucrose 
10mM Et3N 
1mM EGTA 
pH7,4 
FACS buffer (Flow cytometry) 2 % FCS 
2mM EDTA 
0.1% NaN3  
in PBS 
HE buffer (Adenovirus generation) 10mM HEPES 
1mM EDTA 
NH4Cl buffer (Erythrocyte Lyses) 155 mM NH4Cl 
10 mM KHCO3 
1 mM EDTA 
pH 7.4 
PBS 140 mM NaCl 
10 mM KCl 
6,4 mM Na2HPO4x 2H2O 
2 mM KH2PO4  
Sample Buffer (SDS-PAGE)  0,0625mM Tris-HCl pH6,8 
10% glycerol (v/v) 
2% SDS (w/v) 
5% mercaptoethanol (v/v) 
0,05% bromphenolblue (w/v) 
SDS electrophoresis buffer (SDS-
PAGE) 
25mM Tris 
250mM glycine 
0,1% SDS (w/v) 
Stripping buffer (Western Blot) 50mM Tris 
2% SDS (w/v) 
100mM mercaptoethanol,  
pH 6.8  
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B: Abbreviations 
 
 
abbreviation full name 
ActA Actin-assembly inducing protein precursor 
AGE Advanced glycation end product 
BHI Brain heart infusion 
BSA Bovine Serum albumin 
CARD9 Caspase-recruitment domain 9 
CBDC Cod blood dendritic cells 
CBMC Cord blood mononuclear cells 
CLEC-1/2 C-type lectin-like receptor-1/2 
COX-1 Cytochrome c oxidase subunit 1 
COX2 Cyclooxygenase 2 
CpG-ODN CpG-oligodesoxynucleotide 
CRD Carbohydrate recognition domain 
CTLD C-type lectin-like domain 
DAPI 4',6-diamidino-2-phenylindole 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin 
DEC205 Dendritic and epithelial cells, 205 kD  
DECTIN-1 Dendritic cell-associated C-type lectin-1 
DEPC Diethylenepyrocarbonate 
DMEM Dulbecco's Modified Eagle Medium 
EST Expressed sequence tag 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
Flt3-L FMS-like tyrosine kinase 3-ligand 
GABARAPL1 GABA(A) receptor-associated protein like 1 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HEK293 Human embryonic kidney 293 
HEV High endothelial venules 
Hpt Hexose phosphate transporter 
HRP horse radish peroxidase 
HSV Herpes simples virus 
HUVEC Human umbilical vein endothelial cells 
IFN-β Interferon-β 
IL-1 Interleukin-1 
InlA Internalin A 
IRES Internal ribosomal entry site 
ITAM immunoreceptor tyrosine-based activation motif 
JNK c-Jun-NH2-kinases 
LAMP-1 lysosomal-associated membrane protein 1 
LEC Lymphatic endothelial cell 
LLO Listeriolysin 
LOX-1 Oxidized low-density lipoprotein receptor-1 
LplA1 Lipoate ligase A1 
LPS Lipopolysaccharid 
m/pDC Myeloid/plasmacytoid dendritic cells 
MACS Magnetic cell sorting  
MAFA Mast cell Function-associated Antigen 
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MAPK Mitogen-activated protein kinase 
MBP Mannose Binding Protein 
MCMV Murine Cytomegalovirus 
M-CSF macrophage colony-stimulating factor 
MEMalpha Minimum Essential Medium Alpha 
MHC Major histocompatibility complex 
MICL myeloid inhibitory C-type lectin-like receptor 
MOI Multiplicity of infection 
MyD88 Myeloid differentiation primary response gene 88 
NADPH oxidase Nicotinamide adenine dinucleotide phosphate-oxidase 
NCBI National Center for Biotechnology Information 
NFκB nuclear factor κB 
NK cells Natural killer cells 
NKG2 natural-killer group 2 
NKRP NK-cell receptor protein 
NKT Natural Killer T cell 
OCIL Osteoclast inhibitory lectin 
ORF Open reading frame 
oxLDL Oxidized low density lipoprotein 
PAMP pathogen-associated molecular patterns 
PBMC Peripheral blood mononuclear cells 
PBS (+T) Phosphate buffered saline (+Tween) 
PEF penetrating enhancing factors 
PI3K phosphoinositide 3-kinase 
PI-PLC phosphatidylinositol-specific phospholipase C 
PLA2 phospholipase A2  
PLCγ2 phospholipase Cγ2  
PLN Peripheral lymph node 
PMA phorbol myristate acetate 
PMSF Phenylmethylsulfonylfluorid 
PVDF Polyvinylidene fluoride 
RIG-1 Retinoic acid-inducible gene-1 
ROS Reactive oxygen species 
RT-PCR Reverse Transcriptase Polymerase Chain reaction 
SCF Stem cell factor 
SDS Sodium dodecyl sulfate 
TAE Tris-acetate-EDTA 
TGF-β transforming growth factor-β ( 
TIR Toll/interleukin-1 receptor-like domain 
TLR Toll like receptor 
TNF-α Tumour necrosis factor-α 
TPO Thrombopoietin 
TRAF TNF Receptor Associated Factor family of proteins 
TRIF TIR-domain-containing adapter-inducing interferon-β 
UTR Untranslated region 
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C: CD molecules 
 
CD Alternative name Expression pattern 
CD107a LAMP-1 Lysosomal marker, surface of NK upon activation 
CD11b MAC-1 T cells, B cells, NK cells, monocytes, 
granulocytes 
CD14 LPS-R Monocytes, granulocytes 
CD15 LewisX Monocytes, granulocytes 
CD151 SFA-1, PETA-3 platelets, stem cells, endothelium, epithelium 
CD16b FcγR T cells, NK cells, monocytes, granulocytes, 
endothelium 
CD19 B4 B cells, DC 
CD1a R4T6, HTA-1 DC 
CD3 T3 T cells 
CD34 gp105-120 Stem cells, endothelium 
CD4 L3T4, T4 T cells, monocytes, granulocytes  
CD40 Bp50 B cells, DC, stem cells, monocytes, endothelium, 
epithelium 
CD154 CD40L, CD40 Ligand Activated T cells  
CD62L L-Selectin T cells, B cells, NK cells 
CD83 HB15 B cells, DC 
CD94 Kp43 T cells, NK cells 
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